Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Protocol Title: Evaluation of Daily Disposable Silicone  Hydrogel Multifocal Toric Contact 
[CONTACT_512896]: CR-6435
Version: 1.0
Date: 12May [ADDRESS_1052698] Articles :JJVC Investigational Multifocal Toric Contact [CONTACT_767686] A (C3) material with UV/HEV blocker
Key Words: Presby[CONTACT_19555], Multifocal, Astigmatism, Daily Wear, Daily Disposable, 
Dispensing, s enofilcon A , logMAR visual acuity , CLUE questionnaire
Statement of Compliance to protocol, GC P and applicable regulatory guidelines:
This trial will be conducted in compliance with the protocol, ISO [ZIP_CODE] ,1the International 
Conference on Harmonization Good Clinical Practice E6 (ICH -GCP) ,2the Declaration of 
Helsinki ,3and all applicable regulatory requirements.
Confidentiality Statement:
This document contains confident ial information, which should not be copi[INVESTIGATOR_530], referred to, 
released or published without written approval from [COMPANY_012] Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional 
Review Board/Independent Ethics Committee a pproval and informed consent, or as required 
by [CONTACT_767687], Federal and State La ws, as applicable. Persons to whom this information is 
disclosed must be informed that this informatio n is privileged and confidential and that it 
should not be further disclosed without  the written permission of Johnson & Jo hnson Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential and proprieta ry to [COMPANY_012] Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document.
CR-6435, v1.0
Page 1 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION AND DATE ................................ ...................... 6 
SPONSOR NAME [CONTACT_71191] ................................ ................................ ....................... 6 
MEDICAL MONITOR ................................ ................................ ................................ ............. 6 
AUTHORIZED SIGNATURES ................................ ................................ ............................... 7 
CHANGE HISTORY ................................ ................................ ................................ ................ 9 
SYNOPSIS ................................ ................................ ................................ .............................. 10 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS
................................ ................................ ................................ ................................ ................. 16 
1. INTRODUCTION AND BACKGROUND ................................ ................................ ...18 
1.1. Name [CONTACT_126139] ................................ ................ 18 
1.2. Intended Use of Investigational Products ................................ ................................ .18 
1.3. Summary of Findings from Nonclinical Studies ................................ ...................... 18 
1.4. Summary of Known Risks and Benefits to Human Subjects ................................ ...18 
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical 
Study ……………………………………………………………………………………...[ADDRESS_1052699] Articles ................................ ................................ ............................ 25 
6.2. Ancillary Supplies/Products ................................ ................................ ..................... [ADDRESS_1052700] Articles ................................ ................................ ................ 27 
7. STUDY EVALUATIONS ................................ ................................ .............................. 28 
7.1. Time and Event Schedule ................................ ................................ ......................... 28 
7.2. Detailed Study Procedures ................................ ................................ ....................... 29 
VISIT 1 ................................ ................................ ................................ ........................... 29 
CR-6435, v1.0
Page 2 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
VISIT 2 ................................ ................................ ................................ ........................... 37 
VISIT 3 ................................ ................................ ................................ ........................... 43 
VISIT 4 ................................ ................................ ................................ ........................... 47 
FINAL EVALUATION ................................ ................................ ................................ ..49 
7.3. Unscheduled Visits ................................ ................................ ................................ ...50 
7.4. Laboratory Procedures ................................ ................................ ............................. 52 
8. SUBJECTS COMPLETION/WITHDRAWAL ................................ .............................. 52 
8.1. Completion Criteria ................................ ................................ ................................ ..52 
8.2. Withdrawal/Discontinuation from the Study ................................ ........................... 52 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. [ADDRESS_1052701] QUALITY COMPLAINTS .............. 56 
13. ADVERSE EVENTS ................................ ................................ ................................ ...57 
13.1.  Definiti ons and Classifications ................................ ................................ ............. 57 
13.2.  Assessing Adverse Events ................................ ................................ .................... 59 
13.2.1.  Causality Assessment ................................ ................................ .................... 59 
13.2.2.  Severity Assessment ................................ ................................ ...................... 60 
13.3.  Documentation and Follow -Up of Adverse Events ................................ .............. 60 
13.4.  Reporting Adverse Events ................................ ................................ .................... 61 
13.4.1.  Reporting Adverse Events to Sponsor ................................ .......................... 62 
13.4.2.  Reporting Adverse Events to the Res ponsible IEC/IRB and Health Authorities
………………………………………………………………………………[ADDRESS_1052702] KEEPI[INVESTIGATOR_1645]/ARCHIVING ................................ 70 
15.1.  Electronic Case Report Form/Data Collection ................................ ..................... [ADDRESS_1052703] ................................ ................................ ................................ ......70 
15.3.  Trial Registration on ClinicalTrials.gov ................................ ............................... 71 
16. DATA MANAGEMENT ................................ ................................ ............................. 71 
16.1.  Access t o Source Data/Document ................................ ................................ ........ 71 
16.2.  Confidentiality of Information ................................ ................................ .............. 71 
16.3.  Data Quality Assurance ................................ ................................ ........................ 71 
16.4.  Data Monitoring Committee (DMC) ................................ ................................ ....72 
CR-6435, v1.0
Page 3 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
17. CLINICAL MONITORING ................................ ................................ ........................ [ADDRESS_1052704] (IEC/IRB) .......... [ADDRESS_1052705] RETENTION ................................ ................................ ................ 76 
20. FINANCIAL CONSIDERATIONS ................................ ................................ ............ 77 
21. PUBLICATION ................................ ................................ ................................ ........... 77 
22. REFERENCES ................................ ................................ ................................ ............ 77 
APPENDIX A: PATIEN T REPORTED OUTCOMES (STUDY QUESTIONNAIRES) .....79 
APPENDIX B: PATIENT INSTRUCTION GUIDE ................................ ........................... 102 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ................................ ....... 103 
APPENDIX D: LENS FITTING GUIDE ................................ ................................ ............. 104 
APPENDIX E: PRESBY[CONTACT_19544] ................................ .....107 
APPENDIX F: OCULAR DOMINANCE ................................ ................................ ............ 108 
APPENDIX G: BINOCULAR OVER REFRACTION ................................ ....................... 109 
APPENDIX H: ................................ ....[ADDRESS_1052706] REPORTED OCULAR SYMPTOMS ................................ ............. 126 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFR ACTIONS
................................ ................................ ................................ ................................ ............... 128 
 BIOMICROSCOPY SCALE ................................ ................................ ............. 134 
 KERATOMETRY ................................ ................................ .............................. 140 
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION ........................ 142 
 TORIC FIT EVALUATION ................................ ................................ .............. 147 
 DISTANCE LOGMAR VISUAL ACUITY MESAUREMENT PROCEDURE
................................ ................................ ................................ ................................ ............... 152 
 VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION     
TESTING ................................ ................................ ................................ .............................. 156 
APPENDIX I: GUIDELINES F OR COVID -19 RISK MITIGATION ................................ 165 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_1783] ........................ [ADDRESS_1052707] OF FIGURES
Figure 1: Study Flowchart ................................ ................................ ................................ ......[ADDRESS_1052708] OF TABLES
Table 1: Test Articles ................................ ................................ ................................ .............. 25 
Table 2: Ancillary Supplies ................................ ................................ ................................ ....26 
Table 3: Time and Events ................................ ................................ ................................ ....... 28 
Table 4: Disallowed systemic medications ................................ ................................ ............. 53 
Table 5: Examples of major and minor protocol deviations ................................ ................... 55 
CR-6435, v1.0
Page 4 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Table 6:  Historical Binocular Hig h Luminance High Contrast Visual Performance ............ 64 
Table 7: Historical CLUE Scores –2-Week Follow -up................................ ......................... 64 
Table 8: Sample Size Es timates for Primary Endpoints ................................ ......................... 65 
Table 9: Power Analysis for Secondary Endpoints ................................ ................................ 65 
 
CR-6435, v1.0
Page 5 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
PROTOCOL TITLE, NUMBER, VERSION  AND DATE  
Protocol Title: Evaluation of Daily Disposable Silicone  Hydrogel Multifocal Toric Contact 
[CONTACT_512896]: CR-6435
Version: 1.0
Date: 12 May 2021
SPONSOR NAME [CONTACT_126140] S 
[COMPANY_012] Vision Care (JJVC)
[ADDRESS_1052709] be notifie d by [CONTACT_93822]/site by e -mail, fax, or 
telephone within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may 
be contact[CONTACT_19546]. General study related questions 
should be directed towards your assigned clinical research associate.
The Medical Monitoring Plan is maintained as a separate document and inc luded in the Trial 
Master File .
 
CR-6435, v1.0
Page 6 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
AUTHORIZED SIGNATURES  
The signature [CONTACT_299318], including all statement s regarding confidentiality, and according to local legal and 
regulatory requirements and applicable U.S. federal regulations,4ICH guidelines,2ISO [ZIP_CODE] ,1
and the Declaration of Helsinki.3
Author See Electronic Signature [CONTACT_767714] s
Reviewer See Electronic Signature [CONTACT_767715]-6435, v1.0
Page 7 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Reviewer See Electronic Signature [CONTACT_767716]-6435, v1.0
Page 8 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
CHANGE HISTORY  
Version Originator Description of Change(s) and Section 
Number(s) AffectedDate
1.0 Original Protocol 12 May 2021
CR-6435, v1.0
Page 9 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
SYNOPSIS 
Protocol Title Evaluation of Daily Disposable Silicone Hydrogel Multifocal 
Toric Contact [CONTACT_767688], [ADDRESS_1052710], Jacksonville, FL [ZIP_CODE]
Clinical Phase Clinical trial phase: Confirmatory
Design control phase: 2b
Trial Registration This study will be registered on ClinicalTrials.gov based on 
the following: The purpose of the study is for design confirmation, not feasibility.
Test Article Investigational Products: JJVC Investigational Multifocal
Toric Contact [CONTACT_767689] A (C3) 
material with UV/HEV blocker
Wear and Replacement 
SchedulesWear Schedule: The lenses will be used on a daily disposable 
basis.Replacement Schedule: The lenses will be replaced each day  
of wear or if lost or damaged.
Objectives The purpose of the study is to confirm the performance of the 
study lens relative to previously established safety and efficacy criteria.  Study results may also be compared to the results obtained in other studies  through aggregation of results 
in graphs and tables.
P
rimary Objective
The primary objective s of this study are to assess the clinical 
performance of investigational multifocal toric contact [CONTACT_767690]™ 
questionnaire, and visual acuity (logMAR ) after 
approximately two weeks of lens wear.
Secondary Objective
The secondary objectives of this study are to compare the
clinical performance of investigational multifocal toric 
contact [CONTACT_767691]’ habitual correction with 
respect to subjective vision, comfort and lens handling 
measured via the CLUE™ questionnaire after approximately 
two weeks of lens wear.
Exploratory Objectives
Additional exploratory objectives are to evaluate the lens fit
acceptance and toric fit of the investigational multifocal toric
lenses, and the ocular health via slit lamp findings.
CR-6435, v1.0
Page 10 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Study Endpoints All secondary and primary endpoint s are considered at the 2-
week follow -up in the optimized lenses (Visit 4). 
Primary endpoints: 
xBinocular high luminance, high contrast logMAR
visual acuity at distance (4 m), intermediate (64 cm),
and near (40 cm) at 2-week follow-up
xSubjective vision via CLUE™ questionnaire at 2-
week follow-up
Secondary endpoints: 
xSubjective vision score via CLUE™ questionnaire:
change from baseline to 2-week follow-up
xSubjective comfort score via CLUE™ questionnaire:
change from baseline to 2-week follow-up
xSubjective handling score via CLUE™ questionnaire:
change from baseline to 2-week follow-up
Exploratory endpoints: 
xPercentage of eyes with an unacceptable lens fi t during
the study
xPercentage of lens fits with rotation stability within [ADDRESS_1052711] being dispensed lenses for 6 to 8 days, then will return 
for lensoptimization (if needed).  Following the optimization 
visit, the study lenses will be worn for approximately two
weeks, including a follow -up visit after 6 to 8 days. The 
primary endpoint s will be logMAR visual acuity at distance, 
intermediate and near and subjective vision scores. 
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main 
observations.
CR-6435, v1.0
Page 11 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Sample Size Approximately [ADDRESS_1052712] is expected to be in the study for 
approximately 3 weeks. 
Anticipated Study 
PopulationHealthy male and female volunteers with presby[CONTACT_19555],
ametropia (hyperopia or myopia) and astigmatism will be screened as per criteria outlined below.  All volunteers will have baseline measurements taken  to ensure eligibility.  The 
baseline procedures will  occur after inform
edconsent has 
been obtained.  
For a detailed list of procedures see the time and events schedule listed below .
Eligibility Criteria -
InclusionPotential subjects must satisfy all of the following criteria to 
be enrolled in the study:
Inclusion Criteria following Screening
The subject must:
1. Read, understand, and sign the STATEMENT OF
INFORMED CONSENT and receive a fully executed
copy of the form.
2. Appear able and willing to adhere to the instructions
set forth in this clinical protocol.
3.Be at least [ADDRESS_1052713] lens wearer in both eyes
(i.e. worn lenses for at least [ADDRESS_1052714] 4 weeks).
6. Be already wearing a presby[CONTACT_767692] (e.g., reading spectacles over contact
[CONTACT_13276], multifocal or monovision contact [CONTACT_13276], etc.)
or if not respond positively to at least one symptom
on the “Presby[CONTACT_391351]”.
CR-6435, v1.0
Page 12 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Inclusion Criteria at Baseline Evaluation:
7.The subject’s distance spherical component of their
refraction must be in the range of either - 1.25 D to -
3.75 D, or +1.25 D to +3.[ADDRESS_1052715]’s refractive cylinder must be -1.00 D to -
1.50 D in each eye, with the cylinder axes in the
range of 90°±30°.
9.The subject’s ADD power must be in the range of
+0.75 D to +2.[ADDRESS_1052716] corrected distance visualacuity of 20/20-3 or better in each eye.
Eligibility Criteria -Exclusion Potential subjects who meet any of the following criteria will be excluded from participating in the study: 
Exclusion Criteria 
following Screening
The subject must not :
1.Be currently pregnant or lactating.
2.By [CONTACT_6270]-report, have any systemic disease (e.g. Sjögren’s
Syndrome), allergies, infecti ous disease (e.g., hepatitis,
tuberculosis), contagious immunosuppressive diseases(e.g., HIV), autoimmune disease (e.g. rheumatoid
arthritis), or other diseases, by [CONTACT_6270]- report, which are
known to interfere with cont act lens wear and/or
participation in the study.
3.Use systemic medications that may interfere with contact
[CONTACT_93829]. See Section 9.1 for
additional details regarding excluded systemic
medications.
4.Currently use ocular medication ( with the exception of
rewetting drops).
5.Have a ny known hypersensitivity or allergic reaction to
single use preservative free rewetting drops or sodium
fluorescein.
6. Have had any previous, or ha ve any planned, ocular or
intraocular surgery (e.g. radial keratotomy, PRK, LASIK,
cataract surgery, retinal surgery, etc.).
7. Have had previous eyelid injuries, surgeries or procedures
which are known to have caused abnorm al eyelid position
or movement, by [CONTACT_6270]-report.
8.Have participated in any contact [CONTACT_506746] 7 days prior to study enrollment.
CR-6435, v1.0
Page 13 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
9. Be an employee or immediate family member of an
employee of clinical site (e.g., Investigator , Coordinator,
Technician).
10.Have a history of amblyopia or strabismus, by [CONTACT_6270]- report.
11.Have a history of herpetic keratitis, by [CONTACT_6270]-report.
Exclusion Criteria a t Baseline Evaluation
The subject must not:
12.Have ocular allergies, infections or other ocular
abnormalities that are known to interfere with contact [CONTACT_767693]/or participation in the study. This may include,
but not be limited to entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia,
recurrent styes, glaucoma, history of recurrent corneal
erosions, aphakia, or corneal distortion
13.Have any Grade 3 or greater slit lamp findings (e.g.,
edema, corneal neovasculariz ation, corneal staining, tarsal
abnormalities, conjunctival injection) on the FDA scale .
Disallowed 
Medications/Interventions Use of any prescription or over-the-counter (OTC) 
medications that may affect contact [CONTACT_13279].  See 
Section 9.[ADDRESS_1052717] (UADE), or any SAE where relationship to study agent cannot be ruled out, may result in stoppi[INVESTIGATOR_767683].  In the event of a UADE 
or SAE, the Sponsor Medical Monitor may unmask the 
treatment regimen of subject(s) and may discuss this with the Principal Investigator [INVESTIGATOR_97158] a ny further subjects are enrolled.
Ancillary Supplies/ Study-
Specific MaterialsRewetting drops and saline for storing worn lenses. Lens vials 
and caps and materials for returning worn contact [CONTACT_767694].
Principal Investigator(s) 
and Study 
Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.  
CR-6435, v1.0
Page 14 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Figure 1: Study Flowchar t
80 Subjects to Complete (45 myopes, 35 hyperopes)
Potential Subjects Identified Based On:
x Age: At least [ADDRESS_1052718] lens wearers with Presby[CONTACT_767695]
x Refractive Spherical Component either - 1.25D to -3.75D or +1.25D to +3.75D
x Refractive Cylinder:-1.00D to -1.50D with a cylinder axis of 90° ± 30°
x Near Add: +0.75D to +2.50D
x Visual Acuity: Best corrected 20/20-3 or better in each eye
Informed Consent (Visit 1)
Eligibility Criteria
Baseline Information
x Habitual lens type, modality, and contact [CONTACT_94645]. Wear Time
x Baseline CLUE, MRD and CLDEQ-8 Questionnaire, Ocular symptoms, and Entrance Visual Acuity
x Lens Removal, Keratometry, Subjective refraction, Add Determination, Ocular Dominance, Add Refinement, and 
Near Visual Acuity
x Biomicroscopy
Modifications
(up to 2 attempts, 
if necessary)Yes
NoDispensing
x Exit Visual Acuity
x Dispensing Criteria, Subject Instructions
x Schedule Follow-up in 6 to 8 DaysTrial Fitting (Visit 1)
x Lens Selection
x Right Eye Lens Insertion and Lens Damage
x Measure Rotation at 1 Minute and 3 Minutes
x Left Eye Lens Insertion and Lens Damage
x Measure Rotation at 1 Minute and 3 Minutes
x Lens Settling, then Toric Fit Evaluation and Lens Fit Assessment
x Visual Satisfaction, Visual Acuity, Over-Refraction
Follow-up 1 (Visit 2)
x Medical History and Concomitant Medication Review
x Wear Time and Compliance
x CLUE and MRD Questionnaire
x Ocular Symptoms, Subjective Acceptance, Entrance Visual Acuity, and Over-Refraction
x Toric Fit Evaluation and Lens Fit Assessment
Modifications
(if necessary)
Dispensing
x Lens Removal and Biomicroscopy
x Insertion of a New Pair of Study Lenses
x Exit Visual Acuity, Dispensing Criteria, and Subject Instructions
x Schedule Follow-up in 6 to 8 DaysNo
Follow-up 2 (Visit 3)
x Medical History and Concomitant Medication Review
x Wear Time and Compliance
x CLUE, MRD and CLDEQ-[ADDRESS_1052719] Instructions
x Schedule follow-up in 6 to 8 days
Final EvaluationLens Optimization (up to 2 attempts allowed)
x Lens Selection (Right, Left or Both)
x Right Eye Lens Insertion and Lens Damage (if applicable)
x Measure Rotation at 1 Minute and 3 Minutes (if applicable)
x Left Eye Lens Insertion and Lens Damage (if applicable)
x Measure Rotation at 1 Minute and 3 Minutes (if applicable)
x Lens Settling, then Toric Fit Evaluation and Lens Fit Assessment
x Visual Satisfaction, Visual Acuity, Over-RefractionYes
Follow-up 3  (Visit 4)
x Medical History and Concomitant Medication Review
x Wear Time and Compliance
x CLUE, MRD and CLDEQ-8 Questionnaires
x Ocular Symptoms, Subjective Acceptance, Entrance VA, Over-Refraction
x Toric Fitting Evaluation and Lens Fit Assessment
x logMAR Visual Performance
x Lens Removal
CR-6435, v1.0
Page 15 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
COMMONLY USED ABBREVIATIONS , ACRONYMS  AND DEFINITIONS OF 
TERMS  
ADD Plus Power Required For Near Use
ADE Adverse Device Effect
AE Adverse Event/Adverse Experience
BCVA Best Corrected Visual Acuity
BSCVA Best Spectacle Corrected Visual Acuity
CFR Code of Federal Regulations
CLUE Contact [CONTACT_767696]
D Diopter
DMC Data Monitoring Committee
eCRF Electronic Case Report For m
EDC Electronic Data Capture
ETDRS Early Treatment Diabetic Retinopathy Study
FDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonization
IDE Investigational Device Exemption
IEC Independent Ethics Committee
IRB Institutional Review Board
ISO International Organization for Standardization
ITT Intent -to-Treat
JJVC Johnson & Joh nson Vision Care, Inc.
LC Limbus Center
logMAR Logarithm of Minimal Angle of Resolution
MedDRA©Medical Dictionary for Regulatory Activities
MOP Manual of Procedures
NIH National Institutes of Health
OD Right Eye
OHRP Office for Human Research Protections
OHSR Office for Human Subjects Research
OS Left Eye
CR-6435, v1.0
Page 16 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
OU Both Eyes
PD Protocol Deviation
PHI Protected Health Information
PI [INVESTIGATOR_506716]/Serious Adverse Experience
SAP Statistical Analysis Plan
SAS Statistical Analysis System
SD Standard Deviation
SOP Standard Operating Procedure
UADE Unantic ipated Adverse Device Effect
[LOCATION_003]DE Unanticipated Serious Adverse Device Effect
VA Visual Acuity
CR-6435, v1.0
Page 17 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.INTRODUCTION AND BACKGROUND
[COMPANY_012] Vision launched their most recent multifocal contact [CONTACT_767697]®OASYS MULTIFOCAL inMarch, [ADDRESS_1052720] greater than -0.75 D of cylinder, in one or both eyes.  Currently 
there are a limited number of soft toric multifocal lenses available .This study will evaluate 
theperformance of prototype daily disposable mult ifocal toric lenses with a similar optical 
design to ACUVUE®OASYS MULTIFOCAL which are manufactured in s enofilcon A (C3) 
material with an added high energy visible (HEV) light blocker .
1.1. Name [CONTACT_767717] s 
Test Article :  JJVC Investigational Multifocal Toric Contact [CONTACT_767686] A (C3) material with UV/HEV blocker
Refer to Table 1in Section 6.1the protocol.   
1.2. Intended Use of Investigational Products  
The Investigational Test lens is indicated for daily wear for the optical correction of refractive 
ametropia (myopia ,hyperopia) and p resby[CONTACT_618430] -diseased 
eyes who may need up to +2.[ADDRESS_1052721] astigmatism in the range of  -1.00 
D to -1.50 D.   In this study, t he lenses will be used in a populati on of presby[CONTACT_618193]
+1.25 D to +3.75 D or-1.25 D to -3.75 D ofspherical correction, -1.00 Dto-1.50 D of cylinder, 
cylinder axis within 90°± 30°and add powers of +0.75 D to +2.50 D (see Section 3.2).
1.3. Summary of Findings from Nonclinical Studies  
All previous pre -clinical findings were deemed satisfactory prior to proceeding with clinical 
trials on humans. For the most comprehensive noncli nical information regarding JJVC 
Multifocal Toric Contact [CONTACT_288778] A material refer to the latest 
version of the CR-6435 Investigator's Brochure.
1.4. Summary of Known Risks and Benefits to Human Subjects  
For the most comprehensive riskand benefit information regarding JJVC Multifocal Toric 
Contact [CONTACT_288778] A material refer to the latest version of the CR-
6435 Investigator’s Brochure and Informed Consent.
1.5. Relevant Literature References  and Prior Clinical Data Re levant to Proposed 
Clinical Study  
Investigational multifocal toric lenses with the same design and simila r materials have been 
evaluated in two feasibility clinical studies prior to this study. A summary of these studies is 
shown below, and relevant safe ty information for these studies is included in the CR -6435 
Investigator’s Brochure.
wasasingle -arm dispensing evaluation of multifocal toric investigational lenses in a 
myopic population with against -the-rule astigmatism. Lenses used in this s tudy had a slightly 
different material formulation than the lenses being used in the current CR -6435 study.  The 
CR-6435, v1.0
Page 18 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
study lens eswere worn for approximately 2 weeks (with a first follow -up visit after 6 -8 days, 
and second follow -up visit after a further 6 -8 days). Forty subjects were enrolled in the study 
and thirty -seven completed it.    No adverse events were reported.
is an ongoing single -arm dispensing evaluation of multifocal toric investigational 
lenses in a hyper opic population with against -the-rule astigmatism. This study is testing lenses 
with an older formulation (same as the one used in )in comparison with anewer 
formulation (same as the one to be used in the current CR-6435 study ).  In the 2x3 crossover 
study design involving [ADDRESS_1052722] been performed on a 
non-toric multifocal version of the study lens.  Further details of the safety profile of these 
related lens types areincluded in the Investigator’s Brochure.
2.STUDY  OBJECTIVES, ENDPOINTS AND HYPOTHESES
2.1. Objectives 
The main purpose of the study is to confirm the performance of the study lens relative to 
previously established safety and efficacy criteria.  Study results may also be compared to the 
results obtained in other studies through aggregation of results in graphs and tables.
Primary Objective
The primary objective of this study is to assess the clinical performance of investigational 
multifocal toric contact [CONTACT_13276] w ith respect to subjective vision measured via CLUE™ 
questionnaire, and visual acuity ( logMAR ) after approximately two weeks of lens wear.
Secondary Objective
The secondary objective sof this study are to compare the clinical performance of 
investigational multifocal toric contact [CONTACT_767691]’ habitual correction with 
respect to subjective vision, comfort and lens handling measured via the CLUE™ 
questionnaire after approximately two weeks of lens wear.
Exploratory Objectives
Additional exploratory objective sareto evaluate the lens fitacceptance and toric fit of the 
investigational multifocal toric lenses , and the ocular health via slit lamp findings .
2.2. Endpoints  
Primary Endpoint s
Visual Acuity (logMAR)
CR-6435, v1.0
Page 19 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Multiple assessments of binocular and monocular visual acuity will be made during the study, 
butthebinocular measurements made at the 2-week follow -up evaluation using high contrast 
letters in bright illuminance conditions will be the primary endpoint . At distance (4 meters), 
VA is assessed using E TDRS Charts; while near (40 cm) and intermediate (64 cm) assessments 
will be made using reduced Guillon -Poling charts. Visual acuity will be measured using h igh
and low contrast charts in bright illuminance conditions.   Visual acuity will also be measured 
using h igh contrast charts in dim illuminance conditions created by [CONTACT_93839]. See 
 in Appendix Hfor details regarding the collection of 
visual acuity (logMAR). 
CLUE Vision Score
Subjective quality of vi sion will be assessed using theContact [CONTACT_169754] 
(CLUE ™) questionnaire after approximately [ADDRESS_1052723] lenses (comfort, vision, handl ing, and packaging) in a contact -lens wearing population 
in the US, ages 18 -65. Derived CLUE™ scores using Item Response Theory (IRT) follow a 
normal distribution with a population average score of 60 (SD 20) , where higher scores indicate 
a mo re favorable/positive response with a range of 0 -120.A 5-point increase in an average 
CLUE™ score translates into 10% shift in the distribution of scores for population of soft 
contact [CONTACT_19554] .5
Secondary Endpoint s
xCLUE Vision Scores, change from baseline to 2-week follow -up
xCLUE Comfort Scores, change from baseline to 2-week follow -up
xCLUE Handling Scores, ch ange from baseline to 2-week follow -up
Other Exploratory endpoints: 
xPercentage of eyes with an unacceptable lens fi t during the study
xPercentage of lens fits with rotation stabili ty within [ADDRESS_1052724] lens w ill be statistically better than 32points on CLUE
scale for hyperop ic subjects.
CR-6435, v1.0
Page 20 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
3.After approximately 2weeks of wear in the optimized lenses ,the binocular , high -
luminance, high-contrast distance (4 M) logMAR visual acuity of the test lens will be
statistically better than 0.[ADDRESS_1052725] intermediate (64cm) logMAR visual acuity of the test lens
will be statistically better than +0.17 logMAR. This will be determined using
Guillon/Poling LogMAR acuity testing charts.
5.After approximately 2weeks of wear in the optimized l enses ,thebinocular , high -
luminance, high-contrast near (40cm) logMAR visual acuity of the test lens will be
statistically better than +0.17 logMAR. This will be determined using Guillon/Poling
LogMAR acuity testing charts.
Second ary Hypotheses
Secondary hypotheses will be tested for the hyperopes and the myopes separately. 
1.After approximately [ADDRESS_1052726] le ns wearers with presby[CONTACT_19555] ,
ametropia (hyperopia or myopia) and astigmatism .
3.2. Inclusion Criteria  
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
Inclusion Criteria following Screening
The subjec t must:
1.Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a
fully executed copy of the form.
CR-6435, v1.0
Page 21 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
2.Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3.Be at least [ADDRESS_1052727] lens wearer in both eyes (i.e. worn lenses for at least [ADDRESS_1052728] 4 weeks ).
6.Be alr eady wearing a presby[CONTACT_171178] (e.g., reading spectacles over
contact [CONTACT_13276], multifocal or monovision contact [CONTACT_13276], etc.) or if not respond positively
to at least one symptom on the “Presby[CONTACT_391351]”.
Inclusion Cri teria atBaseline Evaluation
7.The subject’s distance spherical component of their refraction must be in the range of
either -1.25 D to -3.75 D, or +1.25 D to +3.[ADDRESS_1052729]’s refractive cylinder must be -1.00 D to -1.50 D in each eye, with the
cylinder axes in the range of 90°± 30°.
9.The subject’s ADD power must be in the range of +0.75 D to +2.[ADDRESS_1052730] corrected distance visual acuity of 20/20 -3 or better in each
eye.
3.3. Exclusion Criteria  
Potential subjects who meet any of the following cr iteria will be excluded from participating 
in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be currently pregnant or lactating .
2.By [CONTACT_6270] -report, have a ny systemic disease (e.g. Sjögren’s Syndrome), allergies, infectious
disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV),
autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by [CONTACT_6270] -report, which are
known to interfere with cont act lens wear and/or participation in the study .
3.Use systemic medications that may interfere with contact [CONTACT_93829].
See Section 9.1for addi tional details regarding excluded systemic medications.
4.Current lyuse ocular medication (with the exception of rewetting drops ).
5.Have a ny known hypersensitivity or allergic reaction to single use preservative free
rewetting drops or sodium fluorescein.
6.Have had any previous, or have  any planned, ocular or intraocular surgery (e.g. radial
keratotomy, PRK, LASIK, cataract  surgery, retinal surgery, etc.).
7.Have had previous eyelid injuries, surgeries or procedures which are known to have caused
abnormal eyelid position or movement, by [CONTACT_6270] -report.
8.Have p articipat edin any contact [CONTACT_71170] 7 days prior
to study enrollment .
9.Be an e mployee or immediate fami ly member of an employee of clinical site (e.g.,
Investigator, Coordinator, Technician) .
10.Have a history of amblyopia orstrabismus , by [CONTACT_6270] -report.
CR-6435, v1.0
Page 22 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
11.Have a h istory of herpetic keratitis , by [CONTACT_6270] -report.
Exclusion Criteria a tBaseline Evaluation
The subject must not:
12.Have ocular allergies, infections or other ocular  abnormalities that are known to interfere
with contact [CONTACT_71171]/or participation in the study. This may include, but not be
limited to entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chal azia, recurrent styes, glauc oma, history of recurrent
corneal erosions, aphakia, or corneal distortion
13.Have a nyGrade 3or greater slit lamp findings (e.g., edema, corneal neovascularization,
corneal staining, tarsal abnormalities, conjunctival injection) on the FDA scale .
3.4. Enrollment Strategy  
Study subjects will be recruited from the Institution/clinical site’s subject dat abase and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials. 
4.STUDY DESIGN AND RATIONALE
4.1. Description of Study Design  
The study is a bilateral, single -masked, single -arm, 4-visit dispensing study .Approximately 
90 (50 myopes and 40 hyperopes) subjects will be enrolled into this study with the target of 
completing approximately 80 (45 myopes and 35 hyperopes) subjects. 
The study begins with an initial visit (Visit 1). If a subject is found to meet all eligibility criteria, 
the subject will be dispensed the study lens in a bilateral fashion. If the subject is dispensed 
study lenses at the initial visit, then three follow -up visits will occur. The first follow -up visit 
will occur approximately one week afte r the initial visit. If necessary, the lens power may be 
modified at Visit 2, then a new pa ir of lenses with the final lens power will be dispensed. The 
second follow -up (Visit 3) will occur approximately 1-week after Visit 2. The 3rdand final 
follow -up evaluation (Visit 4) will occur approximately 1-week after Visit 3. 
4.2. Study Design Rationale  
A single -arm study was chosen to confirm the performance of the study lens relative to 
previously established safety and efficacy criteria. These criteria have been defined based on 
data from previous studies of 1-DAY ACUVUE®MOIST Multifocal (1DAMM) that have 
been successfully marketed since 2015.5Additionally, results from this study may be 
compared to data from a similar single -arm study on amarketed multifocal toric lens .7Data 
from these studies will be compared by [CONTACT_767698] e
study database s are all hard-locked. 
CR-6435, v1.0
Page 23 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
4.3. Enrollment Target and Stud y Duration  
Approximately 50myopic subjects with against -the-rule astigmatism will be enrolled, with the 
aim that at least [ADDRESS_1052731] -1.00 Dto -1.50 D of astigmati sm in both eyes with 90°± 30°
axis.
Lenses in minus powers and plus powers will be  evaluated in two separate phases of the study 
which may run at  different times  depending on when lenses become available.  Each phase of 
thestudy will last approximately [ADDRESS_1052732] complet ed 
the study and the datab ase is finalized. Otherwise, the mas k should be broken only if specific 
emergency treatment/course of action would be dictated by [CONTACT_126110]. In such cases, the Investigator may, in  an emergency, contact [CONTACT_7195]. In 
the event the mask is broken, the Sponsor must be informed as soon as possible. The date, 
time, and reason for the unmasking mus t be documented in the subject record. The Investigator 
is also advised not to reveal the study trea tment assignment to the clinical site or Sponsor 
personnel. 
Subjects who have had their treatment assignment unmasked are expected to return for all 
remaining scheduled evaluations. Subjects who are discontinued may be replaced.
5.3. Procedures for Maintaining and Breaking the Masking  
The test articles mask shall not be broken unless information concerning the lens type is 
necessary for the urgent medical treatment of a subject. The Sponsor must be notified before 
the mask is broken.
When dispensing test articles, the following steps should be followed to maintain 
rando mization codes:
CR-6435, v1.0
Page 24 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.Investigator or designee (documented on the Delegation Log) will consult the lens
fitting schedule/randomization scheme to ob tain the test article assignment for that
subject prior to dispensing .
2.Investigator or designee will record the sub ject’s number on the appropriate line of the
randomization scheme
3.Investigator or designee will pull the appropriate test articles from the study supply.
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed
outside the clin ical site) or not, must be recorded  on the Test Article Accountability
Log in the “Dispensed” section .
6.STUDY INTERVENTION
6.1. Identity of Test Articles 
The following contact [CONTACT_35498]:
Table 1: Test Articles
Test Lens
Name [CONTACT_767718] [CONTACT_767699] A (C3) material with
UV/HEV blocker
Manufacturer JJVC
Lens Material senofilcon A(C3) with chromophore
Nominal Base Curve 8.5
Nominal Diameter 14.3
Nominal Distance Powers (D) -1.00 to -4.00 in 0.25D steps,
+1.00 to +4.00 in 0.25D steps
Nominal Cylinder Powers (D) -1.00
Cylinder axes (º) 70, 90, 110
Nominal ADD Power (D) Low, Mid, High
Water Content 38%
Oxygen Permeability (Dk) 122.0
Wear Schedule in Current Study Daily Disposable
Replacement Frequency Daily
Packaging Form (vial, blister, etc.) Blister
Each subject will wear approximately 42 lenses for  the average 21 day dispensing period, plus 
any additional lenses needed for modifications and replacements. 
CR-6435, v1.0
Page 25 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.2. Ancillary Supplies/Products  
The following solutions will be used in this study:
Table 2: Ancillary Supplies
Single -Use Preservative- Free Rewetting Solutions 
(any of these three options may be supplied)
Solution 
Name/DescriptionEye- Cept®
Rewetting 
DropsScleralFil®
Preservative 
Free Saline 
SolutionLacriPure
Saline Solution
ManufacturerOptics
LaboratoryBausch + 
LombMenicon
PreservativeNon-
PreservedNon-
PreservedNon-Preserved
Stopwatches will be provided to research sites to help with managing the timing of toric fit 
assessments and lens settling .
6.3. Administration of Test Articles  
Test articles will be dispensed to subject smeeting all eligibility requirements, including any 
dispensing requirements set forth in this clinical protocol. Subjects w ill be dispensed an 
adequate supply of test articles to complete the study. Test articles which are lost or damaged 
may be replaced at the discretion of the Investigator.
6.4. Packaging and Labeling  
The test articles will be packaged in blisters as the primary packaging with an investigational 
lens label . The test articles will be in plastic bags as the secondary packaging form. The sample 
study label is shown below:
CR-6435, v1.0
Page 26 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.5. Storage Conditions  
Test articl es will be maintained at ambient temperatures at the clinical site. Test articles must 
be kept under secure conditions.
6.6. Collection and Storage of Samples  
When possible, any lens or test article associat ed with an Adverse Event and/or a Product 
Quality Comp laint must be retained and stored in a glass vial with moderate solution pending 
directions from the sponsor for potential return to JJVC.
6.7. Accountability of Test Articles  
JJVC will provide the Investigator with sufficient quantities of study articles and s upplies to 
complete the investigation. The Investigator is asked to retain all lens shipment documentation 
for the test article accountability records. 
Test article smust be kept in a locked storage cabinet, accessible only to those assigned by [CONTACT_35500]. The Investigator may delegate this activity to authorized study site 
personnel listed on the Site Delegation Log. All test articles must be acc ounted. This includes:
1.What was dispensed for the subject for trial fitting, to wear out of the office, or issued
for the subject to replace appropriately between visits .
2.What was returned to the Investigator unused ,including expi[INVESTIGATOR_35441].
3.The number and reason for unplanned replacements .
The Investigator will collect all unused test articles  from the subjects at the end of the subject’s 
participation. Subject returned unused test articles must be separated from the clinical study 
inventory of un -dispensed test articles and must be labe led with the subject number and date 
of return. Following final reconciliation of test articles by [CONTACT_2037], the Investigator or 
monitor will return all unused test articles to JJVC.
If there is a d iscrepancy between the shipment documen ts and the contents, contact [CONTACT_35501] .
          
CR-6435, v1.0
Page 27 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
7.STUDY EVALUATIONS
7.1. Time and Event Schedule  
Table 3: Time and Events
Visit Information Visit 1
Screening, 
Baseline, 
Treatment 1Visit 2
Treatment 1 
Follow-up 1Visit 3
Treatment 1 
Follow-up 2Visit 4
Treatment 1 
Follow-up 3
Time Point Day 0 7 ± 1 days after 
Visit 17 ± 1 days after
Visit 27 ± 1 days after
Visit 3
Estimated Visit Duration 2.5 hours 1.0 hours 1.0 hours 1.5 hours
Statement of Informed 
ConsentX
Demographics X
Medical History/Concomitant 
Medications/ReviewX
AE/Concomitant Med Review X X X
Habitual Contact [CONTACT_93848] & Wear ScheduleX
Contact [CONTACT_93849] X
Habitual Lens Wear Time X
Study Lens Wear Time X X X
Compliance X X X
Presby[CONTACT_767700]/Exclusion CriteriaX
Patient Reported Outcomes X X X X
Ocular Symptoms X X X X
Subjective Acceptance X X X
Entrance distance and near 
Visual AcuityXX X X
Lens Removal X X X X
Keratometry X
Subjective Sphero-Cylindrical 
RefractionX
Near ADD Determination X
Ocular Dominance X
ADD Refinement X
Near Visual Acuity X
Slit Lamp Biomicroscopy X X X
Baseline Inclusion/ Exclusion X
Lens Selection X O O OO
Right Lens Insertion X O O OO
Right Lens 1 Minute and 3 
Minute RotationX O O O O
Left Lens Insertion X O O OO
Left Lens 1 Minute and 3 
Minute RotationX O O O O
Lens Settling X O O OO
Toric Fit Assessment X O O X O O X X
CR-6435, v1.0
Page 28 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit Information Visit 1
Screening, 
Baseline, 
Treatment 1Visit 2
Treatment 1 
Follow-up 1Visit 3
Treatment 1 
Follow-up 2Visit 4
Treatment 1 
Follow-up 3
Time Point Day 0 7 ± 1 days after 
Visit 17 ± 1 days after
Visit 27 ± 1 days after
Visit 3
Estimated Visit Duration 2.5 hours 1.0 hours 1.0 hours 1.5 hours
Subjective Lens Fit 
AssessmentX O O X O O X X
Visual Satisfaction X O O OO
Study Lens Distance and Near 
Visual AcuityX O O O O
Over Refraction and Visual 
AcuityX O O X O O X X
Lens Power Modification (if 
required)XX
Additional Lens Power 
Modification (if required)X
Collect unworn lenses (if 
required)O
Visual Performance X X
Insert new pair of lenses X X
Exit Snellen Distance and 
Near Visual AcuityXX X
Dispensing Criteria X X X
Dispensing X X
Subject Instructions X X X
Schedule Follow-Up X X X
Final Evaluation X
Note: O denotes Optional items performed if required based on results
7.2. Detailed Study Procedures  
VISIT [ADDRESS_1052733] lenses to accurately assess 
baseline PRO (CLUE and MRD) performance.  If the subject is not wearing their lenses they 
must be rescheduled.  
Visit 1: Screening
Step Procedure Details
1.[ADDRESS_1052734] read, understand, and sign 
the Statement of Informed Consent before 
being enrolled into the study.  The Principal 
Investigator [INVESTIGATOR_022]/her designee conducting the informed consent discussion must also sign the consent form.
Note
:  The subject must be provided a signed
copy of this document.
CR-6435, v1.0
Page 29 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 1: Screening
Step Procedure Details
1.[ADDRESS_1052735]’s year of birth, age, 
gender, race and ethnicity.
1.[ADDRESS_1052736] ’s medical 
history and concomitant medications.
1.[ADDRESS_1052737]’s habitual 
lens type and parameters.
1.[ADDRESS_1052738] 
lens type and power (number of years and 
months).
During the past four weeks, what is the 
minimum number of days per week that the 
subject has worn their lenses for at least [ADDRESS_1052739]’s correction type (i.e. 
monovision, multifocal, sphere with readers, etc.).
1.[ADDRESS_1052740] ’s wear time and 
comfortable wear time with their habitual 
contact [CONTACT_13276].  
1.8Presby[CONTACT_767701] a 
presby[CONTACT_767702].Appendix 
E
1.[ADDRESS_1052741] be answered “yes” and all responses to Exclusion Criteria must be answered “no” for the subject to be considered eligible. 
If subject is deemed to be ineligible after 
screening, proceed to Final Evaluation and complete Subject Disposition. Refraction and Biomicroscopy forms are not required.
Visit 1: Baseline
Step Procedure Details
1.10 Baseline PRO 
(CLUE and MRD) 
and CLDEQ -[ADDRESS_1052742] will evaluate the vision 
characteristics, comfort characteristics, 
handling characteristics, and visual symptoms 
CR-6435, v1.0
Page 30 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 1: Baseline
Step Procedure Details
of their habitual lenses using the PRO (CLUE 
and MRD) and CLDEQ-[ADDRESS_1052743] the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
thesubject’s habitual contact [CONTACT_767703].
For near measurements use the ETDRS [ADDRESS_1052744] remove their habitual lenses 
and store in an approved storage solution.
1.14 Keratometry / SimK Keratometry/SimK will be performed OD 
and OS and the steep and flat dioptric power and corresponding meridians recorded.
1.[ADDRESS_1052745] the refraction and 
distance visual acuity (OD, OS, OU) to the 
nearest letter.
Note:  Best distance visual acuity with 
sphero -cylindrical refraction must be at least 
20/20-3in each eye for the subject to be 
eligible in the study.
1.16 Near ADD 
DeterminationThe near reading addition will be determined 
using the binocular crossed cylinder technique (BCC) at [ADDRESS_1052746] using a +1.[ADDRESS_1052747] the BCC result in the trial frame and 
refine the near prescription with trial lenses (or flippers) under binocular conditions. 
1.[ADDRESS_1052748] the near 
visual acuity (OD, OS, OU).
CR-6435, v1.0
Page 31 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 1: Baseline
Step Procedure Details
1.[ADDRESS_1052749] be answered “yes” and all responses to Exclusion Criteria questions must be answered “no” for the subject to be considered eligible.
If subject is deemed to be ineligible after 
baseline, proceed to Final Evaluation and complete all forms.
Visit 1: Treatment [ADDRESS_1052750] lens parameters (power and lot number).  Appendix 
D
1.[ADDRESS_1052751] 
Complaint form.
1.24 Timed Settling for 
Right LensThe investigator will start a stopwatch as
soon as the right lens is inserted.
Note:  All lenses in this study have toric 
orientation marks at the 6 and 12 o’clock 
CR-6435, v1.0
Page 32 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 1: Treatment [ADDRESS_1052752] degree.At one (1) minute after insertion: Record:
1.The rotational position to the nearest
degree
At three (3) minutes after insertion: Record:
The rotational position to the nearest degree
1.[ADDRESS_1052753] 
Complaint form.
1.26 Timed Settling for 
Left LensThe investigator will start a stopwatch as
soon as the left lens is inserted.
Note:   All lenses in this study have toric 
orientation marks at the 6 and 12 o’clock 
position s.  Rotation measurements are 
made relative to a vertical reference line .
Record base nasal or base temporal rotation 
to the nearest degree.At one (1) minute af
ter insertion: Record:
1.The rotational position to the nearest
degree
At three (3) minutes after insertion: Record:
The rotational position to the nearest degree
1.[ADDRESS_1052754]:
•The rotational position to the nearest
degree
•Lens stability with blink
•Toric fit acceptable or unacceptable
Toric lens fit will be unacceptable if lenses
rotated more than 30 degrees, or lens
stability is worse than 5 degrees movement
CR-6435, v1.0
Page 33 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
with blink. If toric fit is unacceptable,
remove, store, and label the lenses, and
proceed to Final Evaluation.
1.29 Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and tightness 
(push-up test).
xThe subject should not proceed to wear
the lenses if any of the following is
observed:
xpresence of limbal exposure (appearance
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement
(excessive or insufficient) in all three
movement categories (primary gaze,upgaze, and push-up).
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, p
erform a slit-lamp
evaluation, and complete the Final 
Evaluation form.
1.[ADDRESS_1052755]’s vision is acceptable with the lenses.  Allow the subject to look down a hallway or out of a window for distance vision assessments, and for them to read a book, magazine or similar for near vision.  
1.[ADDRESS_1052756] the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
the study contact [CONTACT_93850].
For near measurements use the ETDRS [ADDRESS_1052757] on near vision under monocular and/or binocular conditions.   
CR-6435, v1.0
Page 34 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 1: Treatment 1 Lens Fitting
Step Procedure Details
1.33 Lens Power 
Modification (if applicable)If the subject reports unsatisfactory vision,
or is unable to obtain 20/[ADDRESS_1052758] reports satisfactory vision with the lenses a modification is not re quired however may be 
made at the Investigators discretion based upon their findings on the measured visual acuity and/or
over- refraction.
Note: switching to a non -multifocal lens per 
Step [ADDRESS_1052759] the reason(s) for lens change (select
all that apply):• The settled lens rotation is such that one ofthe other available lens cylinder axis would be   better (use LARS rule to determine the replacement lens cylinder axis)• Power Modification needed• Unsatisfactory Vision• Other (specify reason)
If one or both lenses are modified, repeat 
steps
1.[ADDRESS_1052760] the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
the study contact [CONTACT_93850].
For near measurements use the ETDRS 200 0
Series Chart 1 or 2.
1.35 Dispensing
CriteriaThe lenses may be dispensed for 6-8 days, if 
the following criteria are met:
xDistance Snellen acuity equal to or better
than 20/[ADDRESS_1052761] an acceptable toric and 
general lens fit.
CR-6435, v1.0
Page 35 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 1: Treatment [ADDRESS_1052762] on the following:
xThe lenses will be worn on a daily
disposable wear basis.
xInstruct the subject to bring back allunworn study lenses.
xInstruct the subject no cleaning or
disinfecting solutions will be used for this
lens type.
xIf determined necessary by [CONTACT_767704]-preserved
rewetting drops may be dispensed to be
used as needed for dryness.
xSubjects will be instructed to wear lenses
for a minimum of [ADDRESS_1052763] worn lenses for 6 hours on
the day of the visit.
xSubjects will be instructed to wear their
glasses when not wearing the studylenses .
xA patient instruction booklet will beprovided.
Note: In the event a lens is lost or damaged, 
the subject may return to the investigator site 
fora replacement. As much as reasonably 
possible, a damaged lens should be returned to the investigational site and then returned 
to the 
Sponsor. If lens damage is present, 
complete the Product Quality Complaint Form.
The lens will be stored in a labeled 
vial with saline solution and returned to the 
Sponsor.
1.[ADDRESS_1052764] will be scheduled to return for 
their follow-up appointment in 7±1 days.
CR-6435, v1.0
Page 36 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
VISIT [ADDRESS_1052765] present to Visit 2 wearing the study lense s.
Visit 2: Treatment [ADDRESS_1052766]’s medical 
history or concomitant medications from the previous study visit.  Record any changes, and any adverse events.
2.2 Wear time and 
Comfortable Wear time (Study Lenses)Record the average wearing time and 
comfortable wearing time with the study lenses.
2.3 Compliance Confirm compliance with the prescribed 
wear schedule.
2.4 PRO (CLUE and 
MRD) QuestionnairesThe subject will respond to the Follow-Up
PRO (CLUE and MRD) Questionnaires.
2.[ADDRESS_1052767]’s distance and 
near vision with the lenses is acceptable.
2.[ADDRESS_1052768] the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
the study contact [CONTACT_93850].
For near measurements use the ETDRS
[ADDRESS_1052769] on near vision under 
monocular and/or binocular conditions.   
2.[ADDRESS_1052770]:
•The rotational position to the near est
degree
•Lens stability with blink
•Toric fit acceptable or unacceptable
Toric lens fit will be unacceptable if lenses
rotated more than 30 degrees, or lens
stability is worse than 5 degrees movemen t
with blink. If toric fit is unacceptable,
CR-6435, v1.0
Page 37 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 2: Treatment 1 Follow-Up 1
Step Procedure Details
remove, store, and label the lenses, and
proceed to final evaluation.
2.10 Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and tightness (push
-up test).
The subject should not proceed to wear the 
lenses if any of the following is observed:
xpresence of limbal exposure (appearance
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement
(excessive or insufficient) in all three
movement categories (primary gaze,upgaze, and push-up).
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, p
erform a slit-lamp
evaluation, and complete the Final Evaluation form.
2.11 Lens Power 
Modification (if 
required )If the subject’s vision is unacceptable for at
least one distance or the Investigator 
determines that the visual acuity or over -
refraction are not acceptable then a lens modification must be made. If modifications 
are not needed, proceed to step 2.[ADDRESS_1052771] the reason(s) for lens change (select
all that apply):
• The settled lens rotation is such that one of
the other available lens cylinder axis would be   better (use LARS rule to determine the replacement lens cylinder axis)• Power Modification needed• Unsatisfactory Vision
• Other (specify reason)
CR-6435, v1.0
Page 38 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 2: Treatment [ADDRESS_1052772]
10minutes of settling time between lens 
changes. Note: switching to a non- multifocal 
lensper Step 3 of the Fitting Guide is not an 
available option in this study.
2.12 Lens Selection (if 
required)Select the lens power, based on the Fitting
Guide for each eye needing optimization.
Record the test lens parameters (power an d
lot number).Appendix
D
2.13 Lens Insertion (if 
required)Subjects will insert the lens themselves. If 
the lens is uncomfortable, inspect for damage 
and remove, reinsert or replace as necessary.
Damaged lenses will be stored in labeled vial 
with saline solution, and clearly 
differentiated from the other worn lenses that 
will be shipped back to the Sponsor. Complete the Quality Product Complaint form.
2.14 Timed Settling for 
Lens (if required)The investigator will start a stopwatch as
soon as the lens is inserted.
Note:  All lenses in this study have toric 
orientation marks at the 6 and 12 o’clock 
position .  Rotation measurements are 
made relative to a vertical reference line .
Record base nasal or base temporal rotation 
to the nearest degree.
At one (1) minute after insertion: Record:
a.The rotational position to the
nearest degree
At three (3) minutes after insertion: Record:
a.The rotational position to the
nearest degree
2.15 Lens Settling (if 
required)Allow the study lenses to settle for a 
minimum of 15 minutes.
2.16 Toric Fit Evaluation (if 
required)Record:
•The rotational position to the near est
degree
•Lens stability with blink
•Lens stability with eye versions
CR-6435, v1.0
Page 39 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 2: Treatment 1 Follow-Up 1
Step Procedure Details
•Toric fit acceptable or unacceptable
Toric lens fit will be unacceptable if lenses
rotated more than 30 degrees, or lensstability is worse than 5 degrees movemen
t
with blink. If toric fit is unacceptable,
remove, store, and label the lenses, and
proceed to final evaluation.
2.17 Lens Fit Assessment (if 
required)Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push -up test).
The subject should not proceed to wear the lenses if any of the following is observed:
xpresence of limbal exposure (appearance
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement
(excessive or insufficient) in all three
movement categories (primary gaze,upgaze, and push-up).
If either lens is deem ed unacceptable, the 
subject will be discontinued from the study.  Remove the lenses, p
erform a slit-lamp
evaluation, and complete the Final Evaluation form.
2.18 Determine Visual Satisfaction
(if 
required)Determine if the subject’s vision is acceptable with the lenses.  Allow the subject to look down a hallway or out of a window for distance vision assessments, and for them to read a book, magazine or similar for near vision.  
2.19 Study Lens Distance and Near Visual 
Acuity (if required)Record the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
the study contact [CONTACT_93850].
For near measurements use the ETDRS 200 0
Series Chart 1 or 2.
2.20 Distance Over-Refraction and Distance Visual Acuity
(if required)Perform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination.  
The distance over
-refraction may also be 
refined under binocular conditions.
CR-6435, v1.0
Page 40 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 2: Treatment [ADDRESS_1052773] on near vision under 
monocular and/or binocular conditions.   
2.21 Additional Lens Power 
Optimization (if required)If the subject reports unsatisfactory vision,
or is unable to obtain 20/[ADDRESS_1052774] reports satisfactory vision with the lenses a modification is not required however 
may at the Investigators 
discretion based 
upon their findings on the measured visual 
acuity and/or over - refraction. Note: 
switching to a non -multifocal lens per Step [ADDRESS_1052775] the reason(s) for lens change (select
all that apply):• The settled lens rotation is such that one ofthe other available lens cylinder axis would be   better (use LARS rule to determine the replacement lens cylinder axis)
• Power Modification needed
• Unsatisfactory Vision•O
ther (specify reason)
If one or both lenses are modified, repeat 
steps 2.[ADDRESS_1052776] unworn study 
lenses (if applicable)If the lens power for either eye has been 
modified at this visit, collect any unworn lenses for that eye.If the subject is being discontinued for any reason, collect any unworn lenses.
2.[ADDRESS_1052777] remove the study lenses.
Temporarily store the worn lenses until 
Biomicroscopy has been completed.  If no 
adverse event or PQC was recorded, the worn lenses may be discarded.
2.24 Biomicroscopy  FDA Slit Lamp Classification Scale will be 
used to grade the findings and determine 
eligibility.  
CR-6435, v1.0
Page 41 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 2: Treatment [ADDRESS_1052778] the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
the study contact [CONTACT_93850].
For near measurements use the ETDRS
2000 Series Chart 1 or 2.
2.27 Dispensing
CriteriaThe lenses may be dispensed for 6-8 days, if 
the following criteria are met:
xDistance Snellen acuity equal to or better
than 20/[ADDRESS_1052779] on the following:
xThe lenses will be worn on a dailydisposable wear basis.
xInstruct the subject to bring back allunworn study lenses.
xInstruct the subject no cleaning or
disinfecting solutions will be used for this
lens type.
xIf determined necessary by [CONTACT_767705]-preserved
rewetting drops may be dispensed to be
used as needed for dryness.
xSubjects will be instructed to wear lenses
for a minimum of 6 hours a day, every
day between visits. One missed day of
lens wear between visits is acceptable.
CR-6435, v1.0
Page 42 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 2: Treatment [ADDRESS_1052780] will be scheduled to return for 
their follow-up appointment in 7±[ADDRESS_1052781] present to Visit 3 wearing the study lenses.
Visit 3: Treatment [ADDRESS_1052782]’s medical 
history or concomitant medications from the previous study visit. Record any changes, and any adverse events.
3.2. Wear time and 
Comfortable Wear time (Study Lenses)Record the average wearing time and 
comfortable wearing time with the study lenses.
3.3. Compliance Confirm compliance with the prescribed wear 
schedule.
3.4. PRO (CLUE and 
MRD) and CLDEQ-[ADDRESS_1052783] will respond to the Follow-Up
PRO (CLUE and MRD) and Dry Eye 
Questionnaires.
3.5. Subject Reported 
Ocular SymptomsSubjects will respond to a verbal open-ended 
symptoms questionnaire.
3.6. Subjective 
AcceptanceRecord whether the subject’s distance and 
near vision with the lenses is acceptable.
3.7. Entrance Distance 
and Near Visual AcuityRecord the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
the study contact [CONTACT_93850].
For near measurements use the ETDRS
[ADDRESS_1052784] the OD and OS results and distance visual acuity.  Note: No lens changes are allowed based on 
the over
-refraction.  Appendix 
G
CR-6435, v1.0
Page 43 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 3: Treatment [ADDRESS_1052785]:
•The rotational position to the near est
degree
•Lens stability with blink
•Toric fit acceptable or unacceptable
Toric lens fit will be unacceptable if lenses
rotated more than 30 degrees, or lens
stability is worse than 5 degrees movementwith blink. If toric fit is unacceptable,
remove, store, and label the lenses, and
proceed to final evaluation.
3.10. Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and tightness (push
-up test).
xThe subject should not proceed to wear
the lenses if any of the following is
observed:
xpresence of limbal exposure (appearance
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement
(excessive or insufficient) in all three
movement categories (primary gaze,upgaze, and push-up).
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, p
erform a slit-lamp
evaluation, and complete the Final Evaluation form.
3.11. Visual PerformanceD
istance (4 M) 
Intermediate (64 cm)
Near (40 cm)Visual performance will be recorded OD, OS,
and OU for the following:
Distance, Bright Illuminance
ETDRS Charts 4 M-HC#1, HC#2, HC#3 a nd
LC#1, LC#2 and LC#[ADDRESS_1052786] Intermediate (64 cm) an d
Near (40 cm).
CR-6435, v1.0
Page 44 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 3: Treatment 1 Follow-Up 2
Step Procedure Details
Distance, Dim Illuminance (with Distance
goggles)
ETDRS Charts 4 M-HC#4, HC#5, HC#6
Near, Dim Illuminance (with Near goggles)
Reduced Guillon-Poling charts
High Contrast
Intermediate (64 cm) and Near (40 cm).
Note:
xT h er o o mi l l u m i n a n c em u s tb eb e t w een
7.3 and 7.9 EV.
xDistance, HC-1 Chart luminance
Acceptable EV Range 10.5-10.7.
xGuillon-Poling, Near Chart Luminance
Acceptable EV Range 10.8-11.1.
xDo not use the Mesopic filter for Dim
luminance (Dim luminance will be
simulated by [CONTACT_19561]).
3.12. Lens Removal Have the subject remove the study lenses.Temporarily store the worn lenses until Biomicroscopy has been completed.  If no adverse event or PQC was recorded, the worn 
lenses may be discarded.
3.13. Biomicroscopy  FDA Slit Lamp Classification Scale will be used to grade the findings and determine eligibility.  
If the clearance of the fluorescein needs to be 
expedited, preservative
-free rewetting drops 
or saline may be instilled.  
3.14. Insertion of StudyLe
nsesProvide the subject with a NEW PAIR of
lenses that match the power of the lenses thatwere discarded in step 3.[ADDRESS_1052787] the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
the study contact [CONTACT_93850].
For near measurements use the ETDRS
2000 Series Chart 1 or 2.
3.16. DispensingCrit
eriaThe lenses may be dispensed for 6-8 days, if the following criteria are met:
xDistance Snellen acuity equal to or better
than 20/30 OU
CR-6435, v1.0
Page 45 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 3: Treatment [ADDRESS_1052788] on the following:
xThe lenses will be worn on a dailydisposable wear basis.
xInstruct the subject to bring back allunworn study lenses.
xInstruct the subject no cleaning or
disinfecting solutions will be used for this
lens type.
xIf determined necessary by [CONTACT_767704]-preserved
rewetting drops may be dispensed to be
used as needed for dryness.
xSubjects will be instructed to wear lenses
for a minimum of [ADDRESS_1052789] will be scheduled to return for their follow-up appointment in 7±1 days.
CR-6435, v1.0
Page 46 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
VISIT [ADDRESS_1052790] present to Visit 4wearing the study lenses.
Visit 4: Treatment [ADDRESS_1052791]’s medical 
history or concomitant medications from the previous study visit. Record any changes, and any adverse events.
4.2. Wear time and 
Comfortable Wear time (Study Lenses)Record the average wearing time and 
comfortable wearing time with the study lenses.
4.3. Compliance Confirm compliance with the prescribed wear 
schedule.
4.4. Collect unworn 
lenses (if applicable)The subject will return any unworn lenses.
4.5. PRO (CLUE and 
MRD) and CLDEQ-[ADDRESS_1052792] will respond to the Follow-Up
PRO (CLUE and MRD) and Dry Eye Questionnaires.
4.6. Subject Reported 
Ocular SymptomsSubjects will respond to a verbal open-ended 
symptoms questionnaire.
4.7. Subjective 
AcceptanceRecord whether the subject’s distance and 
near vision with the lenses is acceptable.
4.8. Entrance Distance 
and Near Visual 
AcuityRecord the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with
the study contact [CONTACT_93850].
For near measurements use the ETDRS
[ADDRESS_1052793] the OD and OS results and distance visual acuity.  Note: No lens changes are allowed based on the over-refraction.  Appendix 
G
4.10. Toric Fit Evaluation Record:
•The rotational position to the near est
degree
•Lens stability with blink
•Toric fit acceptable or unacceptable
Toric lens fit will be unacceptable if lenses
rotated more than 30 degrees, or lensstability is worse than 5 degrees movement
with blink. If toric fit is unacceptable,
remove, store, and label the lenses, and
CR-6435, v1.0
Page 47 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 4: Treatment 1 Follow-Up 3
Step Procedure Details
proceed to final evaluation.
4.11. Lens Fit Assessment Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and tightness (push
-up test).
xThe subject should not proceed to wear
the lenses if any of the following is
observed:
xpresence of limbal exposure (appearance
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement
(excessive or insufficient) in all three
movement categories (primary gaze,upgaze, and push-up).
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, p
erform a slit-lamp
evaluation, and complete the Final Evaluation form.
4.12. Visual Performance
Distance (4M) 
Intermediate (64 cm)
Near (40 cm)Visual performance will be recorded OD, OS,
and OU for the following:
Distance, Bright Illuminance
ETDRS Charts 4 M-HC#1, HC#2, HC#3 a nd
LC#1, LC#2 and LC#[ADDRESS_1052794] Intermediate (64 cm) an d
Near (40 cm).
Distance, Dim Illuminance (with Distance
goggles)
ETDRS Charts 4 M-HC#4, HC#5, HC#6
Near, Dim Illuminance (with Near goggles)
Reduced Guillon-Poling charts
High Contrast
Intermediate (64 cm) and Near (40 cm).
Note:
xT h er o o mi l l u m i n a n c em u s tb eb e t w een
7.3 and 7.9 EV.
CR-6435, v1.0
Page 48 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visit 4: Treatment 1 Follow-Up 3
Step Procedure Details
xDistance, HC-1 Chart luminance
Acceptable EV Range 10.5-10.7.
xGuillon-Poling, Near Chart Luminance
Acceptable EV Range 10.8-11.1.
xDo not use the Mesopic filter for Dim
luminance (Dim luminance will be
simulated by [CONTACT_19561]).
4.13. Lens Removal Have the subject remove the study lenses.Temporarily store the worn lenses until Biomicroscopy has been completed.  If no 
adverse event or PQC was recorded, the worn 
lenses may be discarded.
FINAL EVALUATION
The final evaluation will ordinarily take place immediately following the last scheduled 
follow -up visit per the study protocol.  It may also take place at any point th e subject 
discontinues the study or is terminated from the study.
Final Evaluation
Step Procedure Details
F.[ADDRESS_1052795] the refraction and distance visual acuity 
(OD, OS, OU) to the 
nearest letter.
F.[ADDRESS_1052796] the distance Snellen visual acuity (OD, OS
, OU) to the nearest letter , and the 
type of visual correction being worn (habitual lenses, distance spectacles or unaided).
CR-6435, v1.0
Page 49 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
7.3.  Unscheduled Visits  
If, during the investigation, a subject requires an unscheduled visit to the clinical site, the 
following information will be collected at a minimum:
xChief complaint prompting the visit.  If the reason is an adverse event, the applicable
eCRF for the adverse event must b e completed and subject record completed as
appropriate
xDate and time of the visit and all procedures completed at the unscheduled visit
xReview of adverse event and concomitant medications
xDocumentation of any test article dispensed or collected from the s ubject, if applicable
xSlit lamp findings (using the Slit Lamp Classification Scale)
If the Investigator withdraws a subject from th e study, the final study visit case report forms 
must be completed indicating the reas on(s) why the subject was withdrawn. T he subject record 
must be completed documenti ng the date and primary reason for  withdrawal and the study 
CRA notified.
Any ocular and non -ocular Adverse Events that are ongoing at the time of the study visit will 
be followed by [CONTACT_737], within li censure, until they have resolved, returned to pre -
treatment status, stabilized, or been satisfactorily explained.  If further treatment i.e., beyond 
licensure is required, the subject will be refe rred to the appropriate health care provider. 
The followi ng information will be collected during an unscheduled visit.
Unscheduled Visit
Step Procedure Details
U.[ADDRESS_1052797] articles. If 
the reason is other than resupply of previously dispensed lenses, specify the reason for the visit.
U.2 Chief Complaints (if 
applicable)Record the subject’s chief complaints for 
reasons for the unscheduled visit.
U.3 Adverse Events and 
Concomitant Medications Review(if applicable)Review any changes to the subject’s medical 
history or concomitant medications from the previous study visit. Record any changes, and any adverse events.
U.4 Entrance VA (if 
applicable)Record the distance Snellen visual acuity 
(OD, OS , OU) to the nearest letter , and the 
type of visual correction being worn (study 
lenses, habitual lenses, distance spectacles or unaided).
U.5 Subjective Sphero-
cylindrical 
Refraction (if 
applicable)Perform bare-eye subjective spherocylindrical 
refraction with a phoropter (adopt the 
maximum plus to maximum visual acuity 
(MPMVA) approach and use the duo-chrome 
CR-6435, v1.0
Page 50 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Unscheduled Visit
Step Procedure Details
test for binocular balancing) and record the 
best corrected distance visual acuity to the 
nearest letter (OD, OS). 
U.6 Slit Lamp 
Biomicroscopy (if applicable)FDA Slit Lamp Classification Scale will be 
used to grade the findings.  If the clearance of the fluorescein needs to be expedited, preservative
-free rewetting drops may be 
instilled.
U.7 Dispensing (if 
applicable)If the subject requires additional lenses to 
complete the wear period and is eligible to do 
so, provide additional lenses per the
dispensing instructions given in the detailed 
study procedures.
U.8 Toric Fit 
Evaluation (if 
applicable)After lens settling, record:
•The rotational position to the near est
degree
•Lens stability with blink
•Lens stability with eye versions
•Toric fit acceptable or unacceptable
Toric lens fit will be unacceptable if lenses
rotated more than 30 degrees, or lens
stability is worse than 5 degrees movemen t
with blink. If toric fit is unacceptable,
remove, store, and label the lenses, and
proceed to final evaluation.
U.9 Lens FitA
ssessment (if 
applicable)Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push -up test).
xThe subject should not proceed to wear
the lenses if any of the following is
observed:
xpresence of limbal exposure (appearance
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement
(excessive or insufficient) in all three
movement categories (primary gaze,upgaze, and push-up).
If either lens is deemed unacceptable, the subject will be discontinued from the study.  
CR-6435, v1.0
Page 51 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Unscheduled Visit
Step Procedure Details
Remove the lenses, perform a slit-lamp
evaluation, and complete the Final Evaluation form.
U.10 Exit Visual Acuity 
(if applicable)Record the distance Snellen visual acuity 
(OD, OS , OU) to the nearest letter , and the 
type of visual correction being worn (study 
lenses, habitual lenses, distance spectacles or unaided).
7.4. Laboratory Procedures 
None
8.SUBJECTS COMPLETION/WITHDRAWAL
8.1. Completion Criteria  
Subjects are considered to have completed the study if they: 
xprovided informed consent .
xare eligible .
xcompleted all visits
8.2. Withdrawal/Discontinuation from the Study  
A subject will be withdrawn from the study for any of the following reasons:
xSubject death during the study period .
xSubject withdrawal of consent .
xSubject not compliant to protocol
xSubject lost to follow -up.
xSubject no longer meets eligibility criteria (e.g. the subject becomes pregnant) .
xSubject develops significant or serious a dverse events causing discontinuation of study
lens wear .
xSubjects who have experienced a Corneal Infiltrative Event (CIE) .
xInvestigator’s clinical judgment regarding the subject safety reasons (that it is in the
best interest of the subject to stop treatment) .
xSubject missed anystudy visit.
xSubject not compliant with study lens wear schedule .
xSubject not successfully dispensed due to lack of efficacy and safety including poor
vision, poor comfort or unacceptable fit .
CR-6435, v1.0
Page 52 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unschedu led).
xComplete the Final Evaluation, indicating the reason that the subject was discontinued
from the study .
xRecord the spherocylindrical refraction with best corrected distance visual acuity .
xCollect used test article(s) (worn or brought to the visit) fro m the subject and discard
them, unless otherwise stated in Section 7.2.
xCollect all unused test article(s) from the subject .
xMake arrangements for s ubject care, if needed, due to their study participation
An additional subjec tmay be enrolled if a subject discontinues from the study prematurely. 
In cases where a subject is lost to follow -up, every possible effort must  be made to contact [CONTACT_35508]/withdrawal. The measures taken to follow 
up must be documented including two written attempts and a certif ied letter (or equivalent) as 
the final attempt. 
9.PRE -STUDY AND CONCOMITANT INTERVENTION/MEDICATION
Concomitant medications will be documented during screening and updated during the study.  
Disallowed medications and therapi[INVESTIGATOR_93786] .  See the Exclusion criteria for specific details. 
9.1. Systemic Medications  
Certain systemic medications are known to have  a higher likelihood to interfere with contact 
[CONTACT_13279], chiefly by [CONTACT_35509]. A summary of disallowed medications is shown 
inTable 4.Subjects with a history of taking these medications will be allowed to enroll only 
if:
xThe medications h ave been taken on a continual or routine basis for at least [ADDRESS_1052798] 1 week prior to signing the informed consent .
Table 4: Disallowed systemic medications
Class of Drug Common Indication(s) Common Examples
Anticholinergics Irritable bowel syndrome, 
Parkinson’s disease, peptic ulcer, 
cystitis, nasal congestion, cold 
symptoms, overactive bladder, 
COPDBentyl, Spi[INVESTIGATOR_35444], Atrovent, 
Hyosyne, Levsin, Symax 
Fastab, Symax SL, Homax SL, 
Cogentin, Transderm Scop, etc.
Oral Phenothiazines Antipsychotic disorders 
(schizophrenia, mania)Compazine, Mellaril, 
Thorazine, Phenergan, etc.
CR-6435, v1.0
Page 53 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Class of Drug Common Indication(s) Common Examples
Oral/Inhaled 
CorticosteroidsArthritis, colitis, asthma, 
bronchitis, allergic or 
inflammatory conditionsCortisone, Prednisone, 
Hydrocortisone, Medrol, 
Kenalog, Flonase etc.
Oral Retinoids Seborrhea, acne Isotretinoin, Acitretin, 
Alitretinoin, etc. 
Oral Tetracycline Urinary Tract Infection, acne, 
chlamydia, gonorrheaSumycin, Achromycin V, etc.
10.DEVIATIONS FROM THE PROTOCOL
Investigator will notify study sponsor upon identification of a protocol deviation. Protocol 
deviations must be reported to the sponsor within 24 hours after discovery of the protocol 
deviation. The Investigator will report  deviations per IRB/IEC requireme nts. All deviations 
will be tracked ,and corrective actions implemented as appropriate. 
If it becomes necessary for the Investigator to implement a deviation in order to eliminate an 
immediate hazard to the trial subject, the Investigator may implement t he deviation 
immediately without notification to the spons or. Within [ADDRESS_1052799] notify and provi de the rationale to the Sponsor and, as 
required, the IEC/IRB. 
If the deviation potentially impacts the s afety of patient or changes the technical integrity of 
the study, then it must be reported to IEC/IRB. This is a "Major Deviation". Deviations
that contradict the information contained in the Informed Consent/Assent forms will be
considered Major Deviati ons.
Minor deviations have no substantive effect on patien t safety or technical integrity of the 
study. They are often logistical in nature. 
Protocol waivers are prohibited.
Table 5lists examples of deviations that will cons titute major and minor protocol deviations 
for this study. 
CR-6435, v1.0
Page 54 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Table 5:Examples of major and minor protocol deviations
Deviation category Major deviation Minor deviation
Out-of-window visit Visit attended [ADDRESS_1052800] le ns group develop serious expected 
(e.g., definite or probable MK) or unexpected device related a dverse events, the study will be 
suspended. Upon review and consultation with IRB, DMC, and JJVC Safety Review 
committee, the study may be terminated. This potential  stoppi[INVESTIGATOR_656466] [ADDRESS_1052801] lens for 
up to 3 years with an assumed MK rate that is below 0.2% per patient -year. The r ate of 0.2% 
per patient year is the established rate for exten ded wear lenses in adults, which was requested 
by [CONTACT_4760] a criterion for evaluating a contact [CONTACT_35510] 
a pre -IDE submission. To be conservative, 200 indep endent patient years were used in the 
calculation. The probability of observing 2 cases or more incidents of MK is 0.061, and 3 cases 
or more incidents of MK is 0.007 (given an MK rate of 0.2% per patient year). 
The occurrence of one or more Unanticipate d Serious Adverse Device Effect ([LOCATION_003]DE), or 
any SAE where the relationship to study agent cannot be ruled out, may result in stoppi[INVESTIGATOR_35446]. In the event of a [LOCATION_003]DE or SAE, the Sponsor may unmask 
the treatment regimen for the s ubject(s) and will discuss this with the Investigator before any 
further subjects are enrolled.
The Sponsor will determine when a study will be stopped. The Principal Investigator [INVESTIGATOR_767684] s afety or if information 
indicates the study’s results are compromised.
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the st udy if an unreasonable risk is determined. Th e
study can be terminated by [CONTACT_126117], if in their opi[INVESTIGATOR_1649], after a discussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate  all adverse events. If it is 
determined that an adverse event presents an unre asonable risk, the investigation, or that part 
of the investigation presenting the ris k, will be terminated as soon as p ossible.
CR-6435, v1.0
Page 55 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Should the study be terminated (either prematu rely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by [CONTACT_35512].
12.PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS
A Product Quality Complaint (PQC) refers to an y written, electronic, or oral communication 
that alleges deficiencies relate d to the identity, quality, dura bility, reliability, safety, 
effectiveness or performance of test articles after they have been relea sed for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following a re not considered product quality complaints:
xSubject satisfaction inquiries reported vi a “Subjective Questi onnaires” and “Patient
Reported Outcomes (PRO) .”
xClinical test articles that are stored improperly or damaged after receipt at the
investigational s ite.
xLens replacements that occur due to drops/fall -outs.
xDamage deemed by [CONTACT_35513],
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where
there is no deficien cy alleged by [CONTACT_423] .
Within [ADDRESS_1052802] be 
recorded in the EDC system, which will tr igger an automatic email notification to the 
appropriate COM/CRA and Cl inical QA representative. In cases where the EDC system in use 
is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.  
Upon receipt of the EDC notification, the COM/CRA will contact [CONTACT_19568]: 
xDate the complaint was received/recorded in the EDC System (Date of Sponsor
Awareness) .
xWho received the complaint .
xStudy number .
xClinical site information (contact [CONTACT_2300], site ID, telephone number) .
xLot number(s) .
xUnique Subject Identifier(s) .
xIndication of who first observed complaint (site personnel or subject) .
xOD/OS indication, along with whether the lens was inserted .
xAny related AE number if applicable .
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms,
resolution of symptoms, etc.) .
xEye Care Provider objective (sli t lamp) findings if applicable .
CR-6435, v1.0
Page 56 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xConfirmation of product availability for return  (and tracking information, if available),
or rationale if product is not available for return 
Once a complaint is received, it will be assessed by [CONTACT_19569], CRA,  or trained site personnel 
to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or tr ained site personnel will follow Section 13of this 
protocol. If the AE/SAE was potentially the result  of a product quality related deficiency, these 
procedures also applies and will be executed in parallel.  
In some ca ses, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the 
PQC forms will be marked “Intentionally Left Bla nk” or “ILB”.  Justification for ILB must be 
documented.
13.ADVERSE EVENTS
13.1. Definitions and Classifications  
Adverse Event (AE) –AnAE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to  the investigational medical device. ”
Note :This definition includes events related to the investigational medical device or the 
comparator , and to the procedures involved .For users or other persons, this definition is 
restricted to events related to investigational medical devices .1
An AE includes any condition (including a pre -existing condition) that:
1.Was not present prior to the study, but app eared or reappeared following initiation of
the study .
2.Was p resent prior to the study but worsened during the study. This would include any
condition resulting from concomitant illnesse s, reactions to concomitant medications,
or progression of disease states.
Note : Pregnancy must be documented as an adverse event a nd must be reported to the clinical 
monitor and to the Sponsor immediately upon learning of the event.
Serious Adverse Event (SAE) –An SAE is any adverse event thatled to any of the following :
xDeath
xSerious deterioration in the health of the subject that resulted in any of the following:
xLife-threatening illness or injury
xPermanent or persistent impairment of a body structure or a body function
xHospi[INVESTIGATOR_35448] -threatening illness or injury or
permanent impairment to a body structure or a body function.
xChronic disease
xFoetal distress, foetal death or a congenita l physical or mental impairment of birth
defect.
CR-6435, v1.0
Page 57 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Diagnoses and condition s that are considered Ocular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best sp ectacle corrected visual acuity e quivalent to 2 acuity lines
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis
xHypopyon
xHyphemia
xPenetration of Bowman’s Membrane
xPersistent Epi[INVESTIGATOR_35449] –are defined a s events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact [CONTACT_126118], but 
not limited to the following:
xContact [CONTACT_767706] (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epi[INVESTIGATOR_32955] (SEALs)
xAny Temporary Loss of > [ADDRESS_1052803] lens related corneal events -e.g. Epi[INVESTIGATOR_71155] (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinuation > 2 weeks
Non-Significant Adverse Events –are defined as those events that are usually asymptomatic 
and usuall y do not warrant discontinuation of contact [CONTACT_35517] a reduction in 
wear time.  However, the Investigator may choos e to prescribe treatment as a precautionary 
measure .
Diagnoses and conditions that are considered Ocular Non -Significant Ad verse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact [CONTACT_19573][INVESTIGATOR_19534] (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact [CONTACT_89630]-6435, v1.0
Page 58 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xLocalized Allergic Reactions
xAny corneal event not explicitly defined as serious or significant adverse event, which
necessitates temporary lens discontinuation < [ADDRESS_1052804] (ADE) –An ADE is an “adverse event related to the use of an 
investigational medical device. ”
Note 1 :This definition includes adverse events re sulting from insufficient or inadequate 
instructions for use, deployment, implanta tion, installation, or operation, or any malfunction 
of the investigational medi cal device.
Note 2 :This definition includes any event resulting from use error or from intentional misuse 
of the investigational medical device.[ADDRESS_1052805] (UADE) –A UADE is a ny serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated with, the test 
article, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the investigational p lan, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem  associated with the test artic le that relates to the rights, 
safety and welfare of subjects.
13.2. Assessing Adverse Events  
In conjunction with the medical monitor, the Invest igator will evaluate adverse events to ensure 
the events are categorized correctly. Elements of categorization will include:
xSeriousness/Classifications (see definition in section 13.1).
xCausality or Relatedness –i.e. the relationship between the test article, study trea tment
or study procedures and the adverse event (not related ,unlikely related ,possibly
related ,orrelated -see definition in Section 13.2.1 ).
xAdverse Event Severi ty –Adverse event severity is used to assess the degree of
intensity of the adverse event (mild ,moderate ,orsevere -see definition in
Section 13.2.2 ).
xOutcome –not recovered or not resolved ,recovering or resolving ,recovered or
resolved with sequelae ,recovered or resolved ,death related to adverse event , or
unknown .
xActions Taken –none ,temporarily discontinued ,permanently discontinued , orother .
13.2.1. Causality Assessment  
Causality Assessment –A determination of the relationship be tween an adverse event and the 
test article. The test article relationship for each  adverse event should be determined by [CONTACT_192682] r using these explanations:
xNot Related -An adverse event that is not related to the use of the test article, study
treatment or study procedures .
xUnlikely Related –An adverse event for which an alternative explanation is more
likely, e.g. concomitant tre atment, concomitant disease(s), or the relationship of time
suggests that a causal relationship is not likely .
CR-6435, v1.0
Page 59 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xPossibly Related –An adverse event that might be due  to the use of the test article, or
to the study treatment or study procedures. An alternati ve explanation, e.g. concomitant
treatment, concomitant disease(s), is inconclusive. The relationship in time is
reasonable. Therefore, the causal relationship cannot be excluded .
xRelated –An adverse event that is listed as a possible adverse effect (devi ce) or adverse
reaction (drug) and cannot be reasonably exp lained by [CONTACT_4867], e.g.
concomitant treatment of c oncomitant disease(s). The relationship in time is very
suggestive, e.g. it is confirmed by [INVESTIGATOR_5328] -challenge and re -challenge .
13.2.2. Sever ity Assessment  
Severity Assessment –A qualitative assessment of the degree of intensity of an adverse event 
as determined by [CONTACT_126121]/her by [CONTACT_423]. The assessment of 
severity is made irrespective of test article, study tre atment or study procedure relationship or 
seriousness of the event and should be evaluated according to the following scale:
xMild –Event is noticeable to the subject but is  easily tolerated and does not interfere
with the subject’s daily activities .
xModer ate –Event is bothersome, possible requiring additional therapy, and may
interfere with the subject’s daily activities .
xSevere –Event is intolerable, necessitates additi onal therapy or alteration of therapy
and interferes with the subject’s daily activit ies.
13.3. Documentation and Follow -Up of Adverse Events  
The recording and documenting of adverse events (ocular and non -ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical events reported after the su bject’s 
exit from the study will be recorded as adve rse events at the discretion of the Investigator.
Upon finding an adverse event, the Principal In vestigator will document the condition in the 
subject record and in the eCRFs andcomplete the Adverse Eve nt eCRF.  
Complete descriptions of all adverse events must be available in the subject record. All 
Adverse Events including local and systemic re actions not meeting the criteria for “serious 
adverse events” shall be captured on the appropriate case repor t form or electronic data system. 
All adverse events occurring while the subject is enrolled in the study  must be documented 
appropriately regardless of relationship.  
It is the Investigator’s responsibility to  maintain documentation of each reported adv erse event. 
All adverse events will be followed in accordan ce with applicable licensing requirements. Such 
documentation will include the following:
xAdverse event (diagnosis not symptom) .
xDrawings or photographs (where  appropriate) that detail the finding (e.g., size,
location, and depth, etc.) .
CR-6435, v1.0
Page 60 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xDate the clinical site was notified .
xDate and time of onset .
xDate and time of resolution .
xAdverse event classification, severity, and relationship to test articles, as applicable .
xTreatment regimen institute d(where appropriate) , including concomitant medications
prescribed, in accordance with applicable licensing requirements .
xAny referral to another health care provider if needed .
xOutcome, ocular damage (if any) .
xLikely etiology .
xBest corrected visual acuit y at the discovery of the event and upon conclusion of the
event , if the AE is related to the visual system.
Upon discovery of an AE that is deemed ‘possibl y related’ or ‘related’ to the test article or 
study procedures (whether related to the visual syst em or not), an AE review form 
must be completed. Additional dated and in itialed entries should be made at follow -up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment 
eCRF. Where necessary, a culture of the corneal les ion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the date of culture collection and 
laboratory utilized will be recorded. 
Changes in the severity of an AE shall be documented to allow an assessment of the duration 
of the event at each level of in tensity to be performed. Adve rse events characterized as 
intermittent require documentation of the onse t and duration of each epi[INVESTIGATOR_1865]. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.
Subjects who present with an adverse event shall be followed by [CONTACT_737], within 
licensure, until all signs and symptom s have returned to pre -treatment status, stabilized, or 
been satisfactorily resolved. If further treatm ent beyond licensure is required, the patient will 
be referred to the appropriate health care provi der. The Investigator will use his/her clinical 
judgme nt as to whether a subject reporting with an adverse event will continue in the study. If 
a subject is discontinued from the study, it w ill be the responsibility of the Investigator to 
record the reason for discontinuati on. The Investigator will also docum ent the adverse event 
appropriately and complete the Adverse Even t eCRF. Any subjects with ongoing adverse 
events related to the test article, study treatment or study procedures, as of the final study visit 
date, should be followed to resolution of the ad verse event or until referral to an appropriate 
health care provider, as recommended by [CONTACT_737]. Non -ocular adverse events that are 
not related to the test article, study treatmen t, or study procedures may be recorded as 
“ongoing” without further follow -up.
13.4. Reporting Adverse Events 
The Investigator will notify the Sponsor of an adverse event by e -mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
adverse events, and 2 days from discovery for any non -significant adv erse event. In addition, 
CR-6435, v1.0
Page 61 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
a written report will be submitted by [CONTACT_288797]/IRB according to 
their requirements ( Section 13.4.2 ). The report will comment whether the adverse event was 
considered to be related to the test article, study treatment or study procedures.
13.4.1. Reporting Adverse Events to Sponsor  
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/s ignificant adverse events occurring 
during the study period as soon as possible by e -mail or telephone, but no later than [ADDRESS_1052806] igator is obligated to pursue and obtain 
information requested by [CONTACT_35519]. All 
subjects experiencing a serious/si gnificant adverse event must be  followed up and all outcomes 
must be reported.
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject  received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.
In the event of a serious/significant adverse event, the Investigator must:
xNotify the Sponsor immedi ately .
xObtain and maintain in the subject’s records all pertinent medical information and
medical judgment for colleagues who a ssisted in the treatment and follow -up of the
subject .
xProvide the Sponsor with a complete case history which includes a statemen t as to
whether the event was or was not related to the use of the test article .
xNotify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure according to
national regulations .
Unanticipated (Serious) Adverse Device Effect (UADE)
In the event of an U nanticipated (Serious) Adverse Device Effect (UADE), the Investigator 
will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than [ADDRESS_1052807] report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within [ADDRESS_1052808].
Non-Serious Adverse Events
All non -serious adverse events, including non -serious adverse device effects, will be reported 
to the sponsor by [CONTACT_35521] 2 days from discovery.
13.4.2. Reporting Adverse Events to the Resp onsible IEC/IRB and Health Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth 
CR-6435, v1.0
Page 62 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
by [CONTACT_19581]/IRB . Each clinical site will refer to  and follow any guidelines set forth 
by [CONTACT_19582].
The Sponsor will report applicable Adverse Events to the local health authorities according the 
written guidelines, including reporting tim elines. 
13.5. Event of Special Interest  
None
13.6. Reporting of Pregnancy  
Subjects reporting pregnancy (by [CONTACT_6270] -report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once  discontinued, pregnant participants and their 
fetuses w ill not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact [CONTACT_126124] d studies for safety concerns, but due to 
general concerns relating to pregnancy and contact [CONTACT_19584].  Specifically, pregnant wo men are 
discontinued due to fluctuations in  refractive error and/or visual  acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.
14.STATISTICAL METHODS
14.1. General Considerations  
Statistical Analysis will be undertaken by [CONTACT_35522]. A 
general description of the statistical methods to be implemented in this clinical trial is outlined 
below.
All data summaries and statistical anal yses will be performed using the Statistical Analysis 
System ( SAS)software Version 9.4 or higher (SAS Institute, Cary, NC).8Throughout the 
analysis of data, the results for each subject/eye will be used when availa ble for summariza tion 
and statistical analysis. Unscheduled visits will be summariz ed separately and will be excluded 
from the statistical analysis.
Summary tables (descriptive statistics and/or freque ncy tables) will be provided for all baseline 
variable s, efficacy variables and safety variables as  appropriate. Continuous variables will be 
summarized with descriptive s tatistics (n, mean, standard deviation [SD], median, minimum 
and maximum). Frequency count  and percentage of subjects or eyes within each c ategory will 
be provided for categorical data.
14.2. Sample Size Justification  
This study was designed and powered to demonstrate that the binocular high luminance high 
contrast, visual performance (logMAR) of the Te st lens at distance (4 meters), intermediate 
(64 cm) and near (40 cm) after 2-week of lens wear in the optimized lenses is superior to 0.00, 
+0.17 and +0.[ADDRESS_1052809] lens for the hyperopic population is greater than 32 points
and greater than 40 points for the myopic population .The sample size calculation included 
CR-6435, v1.0
Page 63 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
two historical studies,  and Previous hyperopic data was not available 
for the Test lens, therefore, data from was used because it evaluated lenses with a
similar lens design on a hyperopic population .  Data from  was used for the myopic 
population since this study evaluated lenses with the same lens design and similar material as 
the current Test lens on a population of myopic subjects. 
Table 6:Historical Binocular High Luminance High Contrast Visual Performance –2-Week 
Follow -up
Chart Position Mean SD*Minimum Maximum
Distance (4 M) -0.048 0.0943 -0.220 0.280
Intermediate (64 cm) -0.015 0.1183 -0.240 0.320
Near (40 cm) 0.097 0.1318 -0.200 0.500
*SD: Standard Deviation 
**This summary included data from both 
Table 7:Historical CLUE Scores –2-Week Follow -up
CLUE Domain Strata Baseline 
Mean (SD*)2-Week Follow-up
Mean (SD*)
Vision Hyperope 45.5(14.71) 47.3(18.65)
Myope 42.9(15.43) 55.1(20.73)
Comfort Hyperope 50.7(19.70) 60.9(22.38)
Myope 54.5(20.39) 62.7(21.95)
Handling Hyperope 50.9(17.26) 56.6(21.12)
Myope 56.9(16.49) 70.6(18.02)
*SD: Standard Deviation 
Sample size calculations for each primary endpoint were carried out using a [ADDRESS_1052810],with a family wise error rate of 5% . The calculation was performed using 
the POWER11procedure in SAS Version 9.48. The Bonferroni12method was used to adjust 
the type I error for multiple primary hypotheses α = ଴Ǥ଴ହ
ହൌͲǤͲͳ.A power analysis was also 
performed for each secondary hypothesis to test for non -inferiority of the [ADDRESS_1052811] for paired means with alpha=0.05. The power 
Analysis was performed for different scenarios of intraclass correlation and effect sizes. The 
sample size required forall primary endpoints is displayed in Table 8,while the power 
analysis for the secondary endpoints is located in Table 9.
CR-6435, v1.0
Page 64 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Table 8:Sample Size Estimates for Primary Endpoints 
Endpoint Power Sample Size 
Visual Acuity - Distance (4 M) 80.6% 42
Visual Acuity - Intermediate (64 cm) 80.1% 7
Visual Acuity - Near (40 cm) 80.7% 36
CLUE Vision Scores –Hyperopes 80.1% 18
CLUE Vision Scores –Myopes 80.9% 22
Table 9:Power Analysis for Secondary Endpoints
Endpoint Strata correlation Effect size Power 
Vision –CFB* Hyperope
N=350.3 1 42.3%
3 75.0%
0.5 1 65.5%
3 86.0%
Myope
N=450.3 3 78.1%
5 91.7%
0.5 3 88.2%
5 97.1%
Comfort –CFB* Hyperope
N=350.3 3 58.4%
5 75.0%
0.5 3 70.8%
5 86.3%
Myope
N=450.3 3 67.8%
5 83.9%
0.5 3 80.1%
5 92.9%
Handling –CFB* Hyperope
N=350.3 3 64.8%
5 81.2%
0.5 3 76.9%
5 90.8%
Myope
N=450.3 3 82.6%
5 94.3%
0.5 3 92.0%
5 98.5%
*CFB = Change from baseline (calculated as 2 -week follow -up minus baseline )
Represents conservative pow er estimate based on the mo st conservative effect size and intraclass correlation.
While only 42 subjects are required to complete the study based on the sample size calculation, 
the plan is to compare the data from thisstudy toanother study which is similar in design and 
sample size and isassess ingamarketed multifocal toric lens. Therefore, the sample size was 
increased in order to perform a meta -analysis at a later date. Moreover, as shown in Table 9,a
CR-6435, v1.0
Page 65 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
target completion of [ADDRESS_1052812] of the assessed scenarios .
The plan is to enroll 90eligible subjects with a target completion of 80subjects (45 myopes 
and 35 hyperopes) . During the enrollment period, the subject drop -out rate will be closely 
monitored, if an unexpectedly high dropout rate is  observed, then the tar geted total enrollment
number maybe be increased accordingly to ensure that the target numbers of 45 myopes and 
35 hyperopes subjects complete the study. 
14.3. Analysis Populations  
Safety Population:
All subjects who were administered any test article excluding subjects who drop o ut prior to 
administering any test article. At lea st one observation should be recorded.
Per-Protocol Population: 
All subjects who have successfully completed all visits and did not substantially deviate from 
the protocol as determined by [CONTACT_767707] t review committee prior to database hard lock 
(Per-Protocol Population). Justification of excluding subjects with protocol deviations in the 
Per-Protocol Population set will be documented in a memo to file.
Intent -to-Treat (ITT) Population:
All randomiz ed subjects regardless of actual treatment and subsequent withdrawal from study 
or deviation from protocol. At least one observation should be recorded.
14.4. Level of Statistical Significance  
All planned primary analys esfor this study will be conducted with a 2-sided type I family wise 
error rate of 5%. The Bonferroni12method will be used to adjust for the number of primary 
hypotheses tested. Secondary hypotheses will be tested separately with a 2 -sided type I error 
rate of 5% individually. 
14.5. Primary Analysis 
CLUE Vision Scores
Vision scores after approximately 2 -weeks in the optimized lenses will be analyzed using a
linear mixed model. Baseline vision scores ,event (visit 1 : baseline , visit 2 :1-wknon-
optimized ,visit 3 :1-wkoptimized and vi sit 4:2-wkoptimized ), strata (hyperope and myope) 
and the interaction between event and strata will be included in the model as fixed effects. 
Other covariates such as age, gender and add power may be included when appropriate. Site 
will be included as a random effect (G -side).  Residual errors between measurements within 
the same subject across event will be model using one of the following:
xUnstructured (UN)
xCompound Symmetric (CS)
Page 66 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xHeterogenous Compound Symmetric (CSH)
The structure that returns th e lowest corrected Akaike’s Information Criterion (Keselman et al. 
1998)13will be selected as the structure that best fits the data. T he Kenward and Roger method 
will be used for the calculation of the denominator of degrees of freedom.14
Primary hypothesis 1: 
The null and alternative hypothesis for CLUE vision to test for superiority of the Test lens 
relative to the pre -defined threshold of 40 for myopes is as follows: 
ܪ௢:ߤ்௘௦௧൑40
ܪ஺:ߤ்௘௦௧൐40
Superiority will be decl ared if the lower limit of the 95% confidence interval of the adjusted 
mean for the Test lens is greater than 40. i.e. P( ߤ்௘௦௧> 40) ≥ 0.975. 
Primary hypothesis 2: 
The null and alternative hypothesis for CLUE vision to test for superiority of the Te st lens 
relative to the pre -defined threshold of 32 hyperopes is as follows: 
ܪ௢:ߤ்௘௦௧൑32
ܪ஺:ߤ்௘௦௧൐32
Superiority will be declared if the lower limi t of the 95% confidence interval of the adjusted 
mean for the Test lens is greater than 32. i.e. P( ߤ்௘௦௧> 32) ≥ 0.975. 
LogMAR Visual Acuity
Binocular, high luminance, high contrast visual acuity on logMAR scale after approximately 
2-weeks in the optimized lenses will be analyzed using a linear mixed model. 
Position (distance/intermedi ate/near) will be included as the only fixed effect. Site will be 
included as random effect (G -side) .Other baseline characteristics known of importance such 
as age, gender and add power may be included as covariates when appropriate. The covariance 
between residual errors from the same subject across different positions will be selected based 
on the finite -sample corrected Akaike’s Information Criterion (Keselman et al. 1998).13
Covariance str uctures considered may include: Homogenous compound symmetry (CS) and 
Unstructured covariance structure (UN). The structure that returns the lowest Akaike 
Information Criteria Corrected (AICC) will be selec ted as the structure that best fit the data.
TheKenward and Roger method will be used for the calculation of the denominator of degrees 
of freedom.14
Page 67 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Primary hypothesis 3: 
The null and alternative hypothesis for binocular  distance HLHC visual performance to test 
for superiority of the Test lens relative to the pre -defined threshold of 0 logMAR is as follows: 
ܪ௢:ߤ்௘௦௧൒0 logMAR
ܪ஺:ߤ்௘௦௧൏0 logMAR
Superiori ty will be declared if the upper limit of the 95% confidence interval of the adjusted 
mean for the Test lens is below 0 logMAR. i.e. P( ߤ்௘௦௧< 0) ≥ 0.975. 
Primary hypothesis 4: 
The null and alternative hypothesis for binocular near HLHC visual perf ormance to test for 
superiority of the Test lens relative to the pre -defined threshold of 0.17 logMAR is as follows: 
ܪ௢:ߤ்௘௦௧൒0.17 logMAR
ܪ஺:ߤ்௘௦௧൏0.17 logMAR
Superiority will be declared if the upper limit of the 95% confidence interval of the adjusted 
mean for the Test lens is below 0.17 logMAR. i.e. P( ߤ்௘௦௧< 0.17) ≥ 0.975. 
Primary hypothesis 5: 
The null and alternative hypothesis for binocular  distance HLHC visual performance to test 
for sup eriority of the Test lens relative to the pre -defined threshold of 0.17 logMAR is as 
follows:
ܪ௢:ߤ்௘௦௧൒0.17 logMAR
ܪ஺:ߤ்௘௦௧൏0.17 logMAR
Superiority will be declared if the upper limit of the 95% confidence interval of the adjusted 
mean for the Test lens is below 0.17 logMAR. i.e. P( ߤ்௘௦௧< 0.17) ≥ 0.975. 
14.6. Secondary Analysis 
CLUE Vision, Comfort and Handling Scores
Vision, Comfort and Handling scores after approximately 2 -weeks in the optimized lenses will 
be analyzed separately using a linear mixed model. event (visit 1: baseline, visit 2: 1 -wk non -
optimized, visit 3: 1 -wk optimized and visit 4: 2 -wk optimized) , strata (hyperope and myope) 
and the int eraction between event and strata will be included in the model as fixed effects. 
Other covariates such as age, gender and add power may be included when appropriate. Site 
will be included as a random effect (G -side).  Residual errors between measurements within 
the same subject across event will be model using one of the following:
Page 68 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xUnstructured (UN)
xCompound Symmetric (CS)
xHeterogenous Compound Symmetric (CSH)
xSpatial Power (SP(POW))
The structure that returns the lowest corrected Akaike’s Information Criterion (Keselman et al. 
1998)13will be selected as the structure  that best fits the data. T he Kenward and Roger method 
will be used for the calculation of the denominator of degrees of freedom.14
Hypothesis Testing
The null and alternative hypotheses for non -inferiority are as follows and will be conducted 
separately for each strata (hyperopes and myopes) and CLUE vision, comfort and handling : 
ܪைǣο൑െͷ
ܪைǣο൐െͷ
Where οis the change from baseline to 2 -week fo llow-up (2 -week follow up minus baseline). 
Non-inferiority ofthe2-week follow -upCLUE score relative to the baseline CLUE scores of 
subjects’ habitual lens was concluded if the lower li mit of the 95% CI was above -5(Pr:ʹെ
݇ݓݏݑ݊݅݉݈݊݅݁ݏܾܽ݁>-5, ) > 0.975. 
14.7. Other Exploratory Analyses  
Unacceptable lens fitting, Grade 3 + SLFs, absolute rotation and stability will be descriptively 
summarized by [CONTACT_15992] (baseline, 1 -wk follow -upnon-optimized ,1-wk follow -upoptimized and 
2-wk follow -upoptim ized), when applicable.  If unacceptable lens fitting ,Grade 3 + SLFs ,  
rotation stability > 5 degrees an d absolution rotation > [ADDRESS_1052813] dropout is expected to be one of the main reasons of missing data in this clinical trial.
Page 69 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Past clinica l trials don’t provide the evidence th at subject dropout is systematic or not -at
random. To evaluate the impact of missing data, sens itivity analysis will be conducted using
multiple imputation methods if the proportion of subject dropout is greater than t he 15%. The
SAS/STAT procedures PROC MI and PROC MIANAL YZE will be utilized with a parametric
regression method used to make at least [ADDRESS_1052814] KEEPI[INVESTIGATOR_1645]/ARCHIVING
15.1. Electronic Case Report Form/Data Collection  
The data for this study will be captured on e lectronic case report forms (eCRFs) using an EDC 
system (Bioclinica). An authorized data originator will  enter study data into the eCRFs using 
the EDC system. Data collected on equipment that  is not captured in EDC will be formatted to 
the specification of the JJVC database manager and sent to JJVC for analysis.
The clinical data will be recorded on dedicated eCRFs specifically desi gned to match the study 
procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_3786]. The sponsor or sponsor’s representatives will be authorized to gain access to the 
subject recordation for the purposes of monitoring and auditing the study. 
Edit checks, electronic queries, and audit trails ar e built into the system to ensure accurate and 
complete data collection. Data will be transmitted from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual 
Patient Profi les (IPP) including the full audit trail on electronic media in PDF format for all of 
the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study. 
The content and structure of the eCRFs are compliant w ith ISO14155:[ADDRESS_1052815] should be available for the following: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
xvisit dates
Page 70 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xresults of safety and efficacy parameters as required by [CONTACT_35526] -up of adverse events
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion
xreason for early discontinuation of test article or withd rawal from the study, if
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to be the source record.
Adverse event notes must be revie wed and initialed by [CONTACT_737].
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov based on the following: The purpose of the 
study is for design confirmation, not feasibility .
16.DATA MANAGEMENT
16.1. Access to So urce Data/Document  
The Investigator/Institution will permit trial -related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents. Should the 
clinical site be contact[CONTACT_35527]/IRB or regulatory authority, JJVC must be 
contact[CONTACT_19592] [ADDRESS_1052816] and th erefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the 
information derived from this clinical study , the Investigator understands that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor.
16.3. Data Quality Assurance  
Steps will be taken to ensure the accuracy a nd reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and review of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub -
Page 71 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Investigators and clinical site personnel ar e familiar with the protocol and all s tudy-specific 
procedures and have appropriate knowledge of the study article.
Training on case report form completion will be provided to clinical site personnel before the 
start of the study. The Sponsor will review case report forms for accuracy and com pleteness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be  resolved with the Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with applicable regulations pe rtaining to the conduct 
of clinical trials. The clinical sites will provide direct access to study -related source 
data/documents and r eports for the purpose of monitoring and auditing by [CONTACT_71182].
16.4. Data Monitoring Committee (DMC)  
Not applicable.
17.CLINICAL MONITORING
The study monitors will maintain close contact [CONTACT_767708]’s designated clinical site personnel. The monitor’s responsibilities will include:
xEnsuring that the investigation is bei ng conducted according to the protocol, any
subsequent versions , and regulatory requirements are maintained .
xEnsuring the rights and wellbeing of subjects are protected .
xEnsuring adequate resources, including facilities, laboratories, equipment, and
qualified clinical site personnel .
xEnsuring that protocol deviations are documen ted with corrective action plans, a s
applicable .
xEnsuring that the clinical site has sufficient test article and supplies .
xClarifying questions regarding the study .
xResolving study issues or problems that may arise .
xReviewing of study record s and source documentation verification in accorda nce with
the monitoring plan .
18.ETHICAL AND REGULATORY ASPECTS
18.1. Study -Specific Design Considerations  
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new informati on that may affect their decision to continue 
participation. Subjects will be told that their consent to par ticipate in the study is voluntary and 
may be withdrawn at any time with no reason give n and without penalty or loss of benefits to 
which they would otherwise be entitled. Only  subjects who are fully able to understand the 
Page 72 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
risks, benefits, and potential ad verse events of the study, and provide their consent voluntarily 
will be enrolled.
18.2. Investigator Responsibility  
The Principal Investigator [INVESTIGATOR_71157], the investig ational plan, Section 4 of the ICH E6 
guidelines on Good Clinical Practice (GCP) ,2and applicable regulatory requirements. GCP is 
an international e thical and scientific quality standa rd for designing, conducting, recording, 
and reporting studies that involve the particip ation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and well -being of study su bjects are 
protected, consistent with the principles of the Declaration of Helsinki 64th WMA General 
Assembly [ADDRESS_1052817] maintain 
clinical study files in accordance with Section 8 of the ICH E6 guidelines on Good Clinical 
Practice (GCP) ,2andapplicable regulatory requirements.
18.3. Independent Ethics Committee or Inst itutional Review Board (IEC/IRB)  
Before the start of the study, the Investigator (o r Sponsor when applicable) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_767685] g documents (where applicable):
xFinal protocol .
xSponsor -approved informed consent form (and  any other written materials to be
provided to the subjects)
xInvestigator’s Brochure (or equivalent information) .
xSponsor -approved subject recruitment materials .
xInformation on compensation for study -related injuries or payment to subjects for
participation in the study .
xInvestigator’s curriculum vitae, clinical licenses, or equivalent information (unless not
required, as documented by [CONTACT_8134]/IRB) .
xInformat ion regarding funding, name [CONTACT_767719], institutional affiliations, other
potential conflicts of interest, and incentives for subjects .
xAny other documents that the IEC/IRB requests to fulfill its obligation .
This study will be undertaken only after I EC/IRB has given full approv al of the final protocol,
the informed consent form, applicable rec ruiting materials, and subject compensation 
programs, and the Sponsor has received a copy of  this approval. This approval letter must be 
dated and must clearly i dentify the documents being approved.
During the study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate:
xProtocol revisions
xRevision(s) to informed consent for m and any other written materials to be provided to
subjects
xIf applicable, new or revised subject re cruitment materials approved by [CONTACT_35531] -related injuries or payment to subjects for
participation in the study
Page 73 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xInvestigator’s Brochure revisions
xSummaries of the status of the study (at lea st annually or at intervals stipulated in
guidelines of the IEC/IRB)
xReports of adverse events that are serious, unanticipated, and asso ciated with the test
articles, according to t he IRB’s requirements
xNew information that may adversely affect th e safety of the subj ects or the conduct of
the study
xMajor protocol deviations as required by [CONTACT_6179]/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a new Inv estigator is responsible for the study at the clinical site
xAny other requirements of the IEC/IRB
For protocol revisions that increase subject risk, the revisions and applicable informed consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this not ification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable.
18.4. Informed Consent  
Each subject or their representative, must give written consent according to local requirements 
after the nature of the study has been fully e xplained. The consent form must be signed before 
performance of any study -related activity. The consent form that is used must be approved by 
[CONTACT_670624] d by [CONTACT_90818]/IRB. The infor med consent is in accordance with 
principles that originated in the Declaration of Helsinki,3current ICH2and ISO [ADDRESS_1052818]'s dated sign ature. After having obtained the 
consent, a copy of the informed consent form must be given to the subject.
Each subject for this study will complete an a ssent and a parent or legal guardian must give 
written informed consent according to local requiremen ts after the nature of the study has been 
fully explained. The assent and consent forms must be signed before performance of any study -
related activity. The assent and consent forms that are used must be approved by [CONTACT_767709] 74 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Sponsor and by [CONTACT_767710] C/IRB. The assent and informed consent forms should be in 
accordance with principles that origina ted in the Declaration of Helsinki ,3current ICH2and 
GCP guidelines, applicable regulatory requirements, and Sponsor policy. Before entry into the 
study or pre -screening, the Investigator or an authorized mem ber of the clinical site personnel 
must explain to the potential subject and parent and/or legal guardian the aims, methods, 
reasonably anticipated benef its, and potential hazards of the study or pre -screening, and any 
discomfort it may entail . Subjects an d parent and/or legal guardian will be informed that their 
participation is voluntary and that they may withdraw consent to participate at any time. They 
will be informed that choosing not to participate will not affect the care the subject will receive. 
Finally, they will be told that the Investigator will maintain a subject identification register for 
the purposes of long -term follow -up if needed and that their records may be accessed by [CONTACT_763277] g the confidentiality of the 
subject, to the extent permitted by [CONTACT_739879](s) or regulations. By [CONTACT_93870], the subject is authori zing such access and agrees to be contact[CONTACT_767711].
18.5. Privacy of Personal Data  
The collection, processing and disclosure of pe rsonal data and medical information related to 
the Study Subject, and personal data related to  Principal Investigator [INVESTIGATOR_93794] (e.g., name, clinic address and phone number, curriculum vi tae) is subject to 
compliance with the Health Information Portability and A ccountability Act (HIPAA) in the 
[LOCATION_002]15and other applicable personal data protec tion and security laws and regulations. 
Appropriate measures will be employed to safeguard these data, to maintain the confidentiality 
of the person’s related health and medical information, to properly inform the concerned 
persons about the collection and processing of th eir personal data, to grant them reasonable 
access to their personal data and to prevent access by [CONTACT_35532].
All information obtained during the course of the invest igation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by [CONTACT_4718], 
monitors, Sponsor’s personnel and IEC/IRB. No data w ill be disclosed to any third party 
without the express permission of the subjec t concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their 
investigation related activities that, as part of the investigation will have access to the CRFs 
and subject records.
The collection and processing of pers onal data from subjects enro lled in this study will be 
limited to those data that are necessary to i nvestigate the efficacy, safety, quality, and utility of 
the investigational product(s) used in this study.
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protecti on laws and regulations.
The Sponsor ensures that the personal data will be:
xprocessed fairly and lawfully .
Page 75 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xcollected for specified, explicit, and legiti mate purposes and not further processed in a
way incompatible with these purposes .
xadequate, relevant, and not excessive in relation to said purposes .
xaccurate and, where necessary, kept current .
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Su ch consent should also address t he transfer of the data to 
other entities and to other countries.
The subject has the right to request through the Investigator access to his personal data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the request, 
the conditions of the study, and the applicable laws and regulations.
Appropriate technical and organizati onal measures to protect the pers onal data against 
unauthorized disclosures or access, accidental or  unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pers onnel whose responsibilities require access to 
personal data agree to keep the identity of study su bjects confidential .
19.STUDY RECORD RETENTION
In compliance with the ICH/GCP guidelines ,2the Investigator/Institution will maintain all 
CRFs and all subject records that support the data collected  from each subject, as well as all 
study documents as specified in ICH/GCP2and all study documents as specified by [CONTACT_12926](s). The Investigator/Institution will take measures to prevent 
accidental or premature destruction of these documents.
Essential documents must be retained until at least two ( 2)years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical development of the investi gational product. These 
documents will be retained for a longer period if required by [CONTACT_35533]. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these docum ents no longer need to be retained.
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custo dy must be transferred to a person who will 
accept the responsibility. The Sponsor must be notifie d in writing of the name [CONTACT_19619].  Under no circumstance shall the Investigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor.
If it b ecomes necessary for the Sponsor or the appropr iate regulatory authority to review any 
documentation relating to this study, the Investigator must permit access to such reports.
If the Investigator has a question re garding retention of study records, he/s he should contact 
[CONTACT_19599].
Page 76 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
20.FINANCIAL CONSIDERATIONS
Remuneration for study services and expenses will be set forth in detail in the Clinical Research 
Agreement. The Research Agree ment will be signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC 
management represen tative prior to study initiation.
JJVC reserves the right to withhold remuneration for costs associated with protocol violations 
such as:
xContinuing an ineligible subject in the study .
xScheduling a study visit outside the subject’s acceptable visit range .
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:
xQuery resolution .
xCase Report Form signature .
xCompletion of any follow -up action items .
21.PUBLICATION
There is no plan to publish the ou tcome of this investigation.
22.REFERENCES
1.ISO [ZIP_CODE]:2011: Clinical Investigation of Medical Devices for Human Subjects —
Good Clinical Practice. Available at: https://www.iso.org/standard/[ZIP_CODE].html
2.International Conference on Harmonization Good Clinical Practice E6 (ICH -GCP).
Available at: http://www.ich.org/products/guid elines/efficacy/article/efficacy -
guidelines.html
3.Declaration of Helsinki -Ethical principles for Medical Research Involving Human
Subjects. Available at: https://www.wma.net/po licies -post/wma -declaration -of-
helsinki -ethical -principles -for-medical -research -involving -human -subjects/
4.[LOCATION_002] (US) Code of Federal Regulations (CFR). Available at:
https://www.gpo.gov/fdsys/browse/collecti onCfr.action?collectionCode=CFR
5.Wirth R J, et al. Development of the Contact [CONTACT_169754]: CLUE Scales.
Optom Vis Sci. 2016;93(8):[ADDRESS_1052819] Lens .10 February 2021 .
8.SAS Institute Inc: SAS®9.4 Statements: Reference TEC, NC: SAS Institute Inc; 2014.
9.Karkkainen T.   Clinical Study Report , v2.0.  Evaluation of a Novel Toric
Multifocal Contact [CONTACT_767712].  [ADDRESS_1052820] Lens.  15 March, 2021.
11.SAS Institute Inc. 2016 SAS/STAT®14.3 User’s Guide. Cary NC: SAS Institute Inc.
Page 77 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
12.Bonferroni C. Calculation of the insuran ce groups of heads. Studies in Honour of
[CONTACT_35598]. 1935;Rome: Italy:[ADDRESS_1052821]. A Comparison of Two
Approaches for Selecting Covariance Structures in the Analysis of Repeated Measures.
Communications in Statistics —Simulation and Computation. 1998 ;27(3):[ADDRESS_1052822] MG ,Roger JH. Small Sample Inference for Fixed Effects from Restri cted
Maximum Likelihood .Biometrics . 1997;53 :983-997.
15.Health Information Portability and Acc ountability Act (HIPAA). Available at:
https://www.hhs.gov/hipaa/for -professionals/privacy/index.html
Page 78 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OU TCOMES (STUDY QUESTIONNAIRES ) 
Page 79 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
Page 80 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
Page 82 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
Page 83 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
Page 84 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
Page 85 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
Page 86 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
Page 87 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
Page 88 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 11
Page 90 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 12
Page 91 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 13
Page 92 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 14
Page 93 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 15
Page 94 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 16
Page 95 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 17
Page 96 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 18
Page 97 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 19
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 20
Page 99 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 21
Page 100 of 177
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 22
Page 101 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE  
Will be provided separately .
Page 102 of 177
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX A: PACKAGE INSERT (APPROVED PRODUCT)  
Not Applicable , as this study uses Investigational Products .  
Page 103 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX D: LENS FITTING GUIDE  
CR-6435, v1.0
Page 104 of 177JJVC CONFIDENTIAL
 
CR-6435, v1.0
Page 105 of 177JJVC CONFIDENTIAL
 
 
CR-6435, v1.0
Page 106 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX E: PRESBY[CONTACT_767713]-6435, v1.0
Page 107 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX F: OCULAR DOMINANCE  
SCALE
CR-6435, v1.0
Page 108 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX G: BINOCULAR OVER REFRACTION  
CR-6435, v1.0
Page 109 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX H:   
x DETERMINATION OF NEAR ADD ITION
x NEAR logMAR VISUAL ACUITY MEASUREMENT PROCEDURE
x  LENS FITTING CHARACTERISTICS
x SUBJECT REPORTED OCULAR SYMPTOMS
x DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS
x  BIOMICROSCOPY SCALE
x KERATOMETRY
x  DISTANCE AND NEAR VISUAL ACUITY EVALUATION
x  TORIC FIT EVALUATION
x ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE
x VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING
CR-6435, v1.0
Page 110 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
, DETERMINATION OF NEAR ADDITION  
CR-6435, v1.0
Page 111 of 177JJVC CONFIDENTIAL
Title:                          Determination of Near Addition
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 5  
    
CR-6435, v1.0
Page 112 of 177JJVC CONFIDENTIAL
Title:                          Determination of Near Addition
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 5CR-6435, v1.0
Page 113 of 177JJVC CONFIDENTIAL
Title:                          Determination of Near Addition
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 5CR-6435, v1.0
Page 114 of 177JJVC CONFIDENTIAL
Title:                          Determination of Near Addition
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 5CR-6435, v1.0
Page 115 of 177JJVC CONFIDENTIAL
Title:                          Determination of Near Addition
Document Type:  
Document Number :  Revi sion Number:  4
Page 5of 5  
CR-6435, v1.0
Page 116 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE  
CR-6435, v1.0
Page 117 of 177JJVC CONFIDENTIAL
Title:                         Near LogMAR Visual Acuity Measurement Procedure
Document Type:  
Document Number :  Revi sion Number:  8
Page 1of 2CR-6435, v1.0
Page 118 of 177JJVC CONFIDENTIAL
Title:                         Near LogMAR Visual Acuity Measurement Procedure
Document Type:  
Document Number :  Revi sion Number:  8
Page 2of 2CR-6435, v1.0
Page 119 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
, LENS FITTING CHARACTERISTICS  
CR-6435, v1.0
Page 120 of 177JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number : Revi sion Number:  5
Page 1of 5CR-6435, v1.0
Page 121 of 177JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 5     
       
CR-6435, v1.0
Page 122 of 177JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 3of 5CR-6435, v1.0
Page 123 of 177JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 4of 5CR-6435, v1.0
Page 124 of 177JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 5of 5CR-6435, v1.0
Page 125 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
, SUBJECT REPORTED OCULAR SYMPTOMS  
CR-6435, v1.0
Page 126 of 177JJVC CONFIDENTIAL
Title:                         Subject Reported Ocular Symptoms/Problems
Document Type:  
Document Number :  Revi sion Number:  3
Page 1of 1  
  
            
CR-6435, v1.0
Page 127 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  
CR-6435, v1.0
Page 128 of 177JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 1of 5  
CR-6435, v1.0
Page 129 of 177JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 5CR-6435, v1.0
Page 130 of 177JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 3of 5CR-6435, v1.0
Page 131 of 177JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 4of 5CR-6435, v1.0
Page 132 of 177JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 5of 5CR-6435, v1.0
Page 133 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
, BIOMICROSCOPY SCALE   
CR-6435, v1.0
Page 134 of 177JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
CR-6435, v1.0
Page 135 of 177JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
CR-6435, v1.0
Page 136 of 177JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
CR-6435, v1.0
Page 137 of 177JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
CR-6435, v1.0
Page 138 of 177JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
  
CR-6435, v1.0
Page 139 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
KERATOMETRY  
CR-6435, v1.0
Page 140 of 177JJVC CONFIDENTIAL
   
 
 
   
GRADING     
SCALE    
xDiopters (0.125 steps) and/or Millimeters
xQuality:  Clear 
    Mild distortion 
    Moderate distortion 
    Severe distortion    
 
  
 
CR-6435, v1.0
Page 141 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
CR-6435, v1.0
Page 142 of 177JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 4  
CR-6435, v1.0
Page 143 of 177JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number : Revi sion Number:  4
Page 2of 4CR-6435, v1.0
Page 144 of 177JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 4CR-6435, v1.0
Page 145 of 177JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 4CR-6435, v1.0
Page 146 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
TORIC FIT EVALUATION  
CR-6435, v1.0
Page 147 of 177JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  6
Page 1of 4CR-6435, v1.0
Page 148 of 177JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  6
Page 2of 4CR-6435, v1.0
Page 149 of 177JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number : Revi sion Number:  6
Page 3of 4 
CR-6435, v1.0
Page 150 of 177JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  6
Page 4of 4CR-6435, v1.0
Page 151 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DISTANCE LOGMAR VISUAL ACUITY MESAUREMENT 
PROCEDURE  
  
CR-6435, v1.0
Page 152 of 177JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 4 
 
Page 1 of 3 
   
CR-6435, v1.0
Page 153 of 177JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 4 
 
Page 2 of 3 
  
CR-6435, v1.0
Page 154 of 177JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 4 
 
Page 3 of 3 
 CR-6435, v1.0
Page 155 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 VISUAL ACUITY CHART LUMINANCE AN D ROOM ILLUMINATION     
TESTING  
  
CR-6435, v1.0
Page 156 of 177JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number : Revi sion Number:  4
Page 1of 8CR-6435, v1.0
Page 157 of 177JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 8CR-6435, v1.0
Page 158 of 177JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 8CR-6435, v1.0
Page 159 of 177JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 8CR-6435, v1.0
Page 160 of 177JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 5of 8CR-6435, v1.0
Page 161 of 177JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 6of 8CR-6435, v1.0
Page 162 of 177JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number : Revi sion Number:  4
Page 7of 8CR-6435, v1.0
Page 163 of 177JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 8of 8CR-6435, v1.0
Page 164 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX I: GUIDELINES FOR COVID -19 RISK MITIGATION  
CR-6435, v1.0
Page 165 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
1.0 PURPOSE
The purpose of this doc ument is to provide guidelines for the re -opening or initiation of clinical study sites 
participating in Johnson &Johnson Vision Care, Inc. ( JJVCI )clinical studies dur ing the COVID -19
pandemic.
2.0 SCOPE
This document provides guidelines for Johnson &Johnson Vision Care ( JJVCI )to address the potential risks 
from COVID -[ADDRESS_1052823] from the date of approval through th e date of retirement of this Work 
Instruction. At a minimum ,this Work Instruction will be  reviewed and updated on a quarterly basis, a s
appropriate.
NOTE:  Re-opening of s ites outside of the US will be evaluated on a country by [CONTACT_19605].
3.0 DEFINITIONS
American Academy of Optometry (AAO): The American Academy of Optometry is an organization of 
optometrists based in Orlando, Flor ida. Its goal is to maintain and enhance excellence in optometric 
practice, by [CONTACT_35582]. The AAO holds an annual 
meeting, publishes a monthly scientific journal, give s credentials to optometrists  through the fellowship 
process and publishes position statements.
American Optometric Association ( AOA ):The American Optom etric Association, founded in 1898, is 
the leading authority on quality care and an advocate for our nation's health, representing more than 44,000 
Doctors of Optometry (O.D.), optometric professionals, and optometry students. Doctor of Optometry take 
a leading role in patient care with respect to eye and vision care, as well as general health and well -being. 
As primary health care providers, Doctor of Optometry have extensive, ongoing training to examine, 
diagnose, treat and manage ocular disorders, diseas es and injuries and sys temic diseases that manifes t in the 
eye. The American Optometric Asso ciation is a federation of state, stud ent, and armed forces optometric 
associations. Through these affiliations, the AOA serves me mbers consisting of optometrists, students of 
optometry, paraoptometric assistants a nd technicians. The AOA and its aff iliates work to provide the public 
with quality vision and eye care.
Center sfor Disease Control and Prevention (CDC ):The Centers for Disease Control and Prevention is a 
national public health institute in the [LOCATION_002]. It is a [LOCATION_002] federal agency, under the 
Department of Health and Human Services, and is headquartered in Atlanta, Georgia.
COVID -19: Current outbreak of respi[INVESTIGATOR_35468] a novel coronavirus. The virus has been 
named “S ARS -CoV -2” and the disease it causes has been  named “Coronavirus Disease 2019” (COVID -
19).
Clinical Study: Voluntary research studies cond ucted in people and designed to answer specific questions 
about the safety or effectiveness of drugs, vaccines, other therapi[INVESTIGATOR_014], or new ways of using existing 
treatments. May also be called clinical trials, studies, research, trials, or protocols.
Clinical Study Site: Location where a clinical study is  conducted, such as a doctor’s office, university, or 
laboratory. Clin ical studies are conducted by [CONTACT_35583](s) responsible for the 
conduct of the clinical study at a study site. If a stud y is conducted by a team of individuals, the 
Investigator is the responsible leader  of the team and may be called the Principal Investigator.
Clinical Operations Manager (COM) :The [COMPANY_012] Vision Care ( JJVC I) individual 
responsible for the overall ma nagement of a clinical trial.
CR-6435, v1.0
Page 166 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
Monitor: Anindividual designated to oversee the progress of a clinical study and ensure that it is 
conducted, recorded, and reported in accordance with  the protocol, Standard Operating Procedures (SOPs), 
Good Clinical Practice (GCP), and ap plicable regulatory requirements.
Medical Safety Officer (MSO) :Physician who has prim ary accountability in their product portfolio for 
product health and safety, and who serves as an independent medical voice for patient safety.
Safety Management Team (SMT) :A cross -functional, collaborative team responsible for review, 
assessment and eva luation of medical safety data arising from any source throughout the product life cycle.
4.[ADDRESS_1052824] the health ,safety
and well -being of particip ants and site staff. If, at an y time, a participant’s safety is considered to be at risk, 
study intervention will be discontinued, and study follow -up will be conducted as outlined in the protocol.  
During the COVID -19 pandemic, the additional risks liste d below need to be considered for study participants 
and study personnel :
Additional Risks Related to the COVID -19 Pandemic:
xThe p ossible transmission of the Coronavi rusinfection and consequent complications, beyond the 
risk of adverse events due to the investigational device and/or procedures .
xThe risk may be higher in an op tometric clinical study because of the close contact [CONTACT_126133] (since the investigator
must make the measurements close to the subject’s face) and, in addition the need for multiple 
follow -up visits/exams which may expose the subject to other patients and/or healthcare 
professionals who might be transmitting the virus ,even if they do not have symptoms.
xPotential disruptions to the study may be nece ssary due to current or future pandemic -related 
emergency restrictions, which may lead to delays in scheduled follow -up visits.
xSubjects experienc ingan adverse event related to contact [CONTACT_126134] -19restrictions. In this event, a ll assessments that can be conducted virtually will be 
completed by [CONTACT_126135], including
anunscheduled visit, up to discontinuation from the study , as appropriate .
Ifastudy subject is found to  have contracted COVID -19during participation in astudy, he/she will be 
discontinued from the study and follo wed until COVID -19Adverse Event (AE) resolution.
To help minimize the above potential risks, JJVCI recommend reviewing/complying with local, state, 
and governmental guidance for COVID -19 risks. 
JJVC Iwill provide the following study specific documents wi th language pertaining to COVID -19 risks:
4.1.1 Informed Consent :
Will include information concerning the study -associated risks relate d to the COVID -19 pandemic 
in bold font and/or boxed on the first page of the I nformed Consent document:
CR-6435, v1.0
Page 167 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
STUDY ASSOCIATED RISKS RELATED TO COVID -19 (CORONAVIRUS ) PANDEMIC
It is important to note that this  study will be conducted, at leas t in part, during the COVID -[ADDRESS_1052825] for you. Thi s is particularly important for this 
study due, in part, to the closeness of the doctor during the study examinations. 
The potential effects of the dise ase are not fully known, at th is time, and may include long -term serious health 
consequences. In sever e cases, this may result in hospi[INVESTIGATOR_5478]/or death. Based on current knowledge from the 
Center sfor Disease Control and Prevention (CDC), those at high -risk for severe illness from COVID -19 include 
older adults and people w ith underlying medical cond itions. 
During this study, all appropriate measur es will be taken to minimize risks in cluding the use of personal protective 
equipment such as masks and glov es, as well as proper sanitization. This is in conformance to guidance from the 
CDC, local healt h departments, and the state and county in which the study doctor’s office  is located. However, 
these measures may not completely eliminate th e risks associated with contracting COVID -19. 
If you are found to have contracted COVID -19 or feel ill with flu -like symptoms during pa rticipation in the study, 
you will not be permitted to continue in -office study follow -up visits ,but you will receive instructions and your 
condition will be monitored by [CONTACT_35586]/or study staff.
4.1.[ADDRESS_1052826](Attachment -B):
Will include COVID -[ADDRESS_1052827] JJVCI clinical 
studies. The risk controls are consistent with CDC, AOA, AAO Guidance. The Princip al
Investigator will review/sign the study specific  checklist prior to the Site Initiation Meeting.
4.1.3 Protocol Compliance Investigator(s) Signature [CONTACT_3490] :
Will include a statement indicating thatthePrincipal Investigator ( PI)agrees to conduct the study 
in compliance with all local, state, and governmental guidance’s for COVID -[ADDRESS_1052828] read the sugges ted guidance provided by [CONTACT_19610] -19 risk mitigation,
(COVID -19 Work Instruction in the Appendix of this protocol) .I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks.
4.1.4 Study Site Initiation Training Slides :
Will include sug gestions to help mitigate potential transmission of COVID -19. Suggestions may 
include maintaining social distan cing in the clinical site by [CONTACT_126138] p atients,
wearing proper PPEs, frequ ent disinfection, and installing shields on the s lit lamp and other 
applicable equipment .
5.[ADDRESS_1052829] VISITS
Potential disruptions to the study may be nece ssary due to current or future pandemic -related emergency 
restrictions .  Possible disruption of the study as a result of COVID -19 control measures may lead to delays 
in scheduled follow -up visits.
Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID -[ADDRESS_1052830]’s concerns or fears about COVID -19risk.When appropriate , the remote 
assessment willbe conducted to the extent possible.  Discussions with the subject during remote assessments 
may include:
CR-6435, v1.0
Page 168 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: [ADDRESS_1052831] article when applicable and feasible. 
Change of Medical History 
(Adverse Events) and Concomitant Medications / 
Therapi[INVESTIGATOR_35469] w ith the subject/parents.
Review the subject’s concomitant medications/therapi[INVESTIGATOR_35470].
Wearing Time and 
ComplianceRecord the average wearing time (in cluding number of hours per day 
during weekdays and weekends, and number of days per week).
Confirm compliance with the prescribed wear schedule.
xRecord and discuss the lens wear compliance based on the 
subject’s self -report. For example, the subjects w ill be asked the 
time of the day the subject typic ally puts on the study lenses in the 
morning and takes off in the evenin g, the number of days per week 
lenses were worn, and the number of consecutive days the subject 
didn’t wear the study lenses, etc.
The discussion with the subject w ill be documented in EDC under Tele -Visit and a minor protocol deviation 
will be noted. If during the telephone consultation ,asubject states he/ shewish esto discontinue participating 
in the study, instruct the subject to s top wearing the study lenses and schedu le the subject to return to the 
clinic for a Final Evaluation at  the at earliest possible tim e. Subjects should return all unused lenses to the 
clinic at the last visit.
Changes in study visit schedules, missed visits , or participant discontinuations may lead to missing data, 
including data related to protocol -specified procedures. Case report forms should capture specific 
information regarding the basis of missing data, including the relationship to the COVID -[ADDRESS_1052832] DURING PANDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may have an impact on the conduct 
of this clinical study due to, for example, self -isolation/quarantine by [CONTACT_19611] -site personnel; 
travel restrictions/limited access to public places, including Optometry Clinics ; and changes in clinic 
procedures required to address the COVID -19 challenge.
Every effort should be made  to adhere to protocol -specified assessments f or study participants, including 
follow -up. However, if scheduled visits cannot be conducted in person at the study site it is suggested that 
assessments be performed to the extent possible remotely/virtually or delayed until such time that on -site 
visits can be resumed in order to continue participant monitoring in accordance with the protocol where 
possible. At each con tact, participants will be interviewed to collec t safety data. Key efficacy endpoint 
assessments should be performed if required and as fe asible.
Modifications to protocol -required assessments may be permitted via COVID -19 Appendix after consultation 
with the participant, investig ator, and the sponsor. Missed assessments/visits will be captured in the clinical 
trial management system for pro tocol deviations. Interruptions of test article wear or discontinuations of 
study interventions and withdrawal from the study should be documented with the prefix “COVID -19-
related” in the case report form (CRF).
CR-6435, v1.0
Page 169 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: [ADDRESS_1052833] the sponsor’s responsible 
medical monitor to discuss initial plan s for study intervention and follow -up. The medical monitor will 
notify the Safety Management Team of a ny subject(s) that have reported “COVID -19”, “ Asymptomatic 
COVID -19”, or “Suspected COVID -19” adverse events within [ADDRESS_1052834] as a result of the COVID -19 pandemic will be summarized in the 
clinical study report.  
COVID -19 screening procedur es that may be mandated by [CONTACT_299317].
Monitoring Visits
When on -site monitoring by [CONTACT_19613] ,the sponsor’s site monitor w ill contact [CONTACT_19614]. In such cases, on -site monitoring visits will resume when feasible, with
increased frequency to address th e source data verification backlog.
Even with staffing lim itations during this COVID -[ADDRESS_1052835] process. When conditions permit, all 
parties involved in this clinical  trial should communicate relevant information in a timely  manner so that 
all relevant parties remain  sufficiently informed.
6.1.1 Study Site Initiation:  
During the period that this Work Instruction is in effect , Site Initiation Meetings and training of 
study site staff will be conducted remotely .The JJVCI study team will conduct tr aining via Skype, 
Zoom, Microsoft Teams or similar software as well as utilize online training materials ,as applicable.  
Study site training will be documented utilizing Site Initiation Report
On-site visits may be considered when, for example, hands -on training or evaluation of site facilities 
is required. While on site, the Clinical Research Associate ( CRA )will follow all local, state, and 
governmental policies for COVID -19 Risk Mitigation, including socia l distancing, wearing of PPE, 
etc. as applicable for the lo cation of the study site.
6.1.2 Interim Monitoring Visits (if applicable) :
During the period that this Work Instruction is in effect, Interim Monitoring On-site v isits will be 
kept to a minimum and include only those tasks that the CRA cannot perform remotely (e.g., source 
document verification , test article reconciliation, etc.) .
To ensure data integrity during the conduct of all JJVC studies, clinical study teams will follow the 
study specific Clinical Monitoring Plan
While on site, the CRA will follow all local, state,  and governmental policies for COVID -19 Risk 
Mitigation, including social distancing, wearing of PP E, etc. as applicable for the location of the 
study site.
CR-6435, v1.0
Page 170 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
6.1.3 Study Site Closure:  
During the period that this Work Instruction is in effect, the durati on of the Study Site Closure Visit 
willbe lim ited to tasks that the CRA cannot perform re motely (e.g., source document verification, 
test article final rec onciliation and return, etc.).  
CR-6435, v1.0
Page 171 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
Attachment A: Study Site Correspondenc e
XXXX XX, 2020
Re: COVID -19 Mitigation Plan, << CR-xxxx /protocol title>>
Dear <<Princip alInvestigator>> and Study Team,
Coronavirus (COVID -19) has impacted several communities and busi ness activities over the past several months. 
While we work toward the successful  conduct of clinical studies, our commitme nt continues to be the safety of 
patients, healthcare professi onals, and to our communities. 
Therefore, we would like to share th e following revisions/additions related to the above referenced Johnson & 
Johnson Vision Care company sponsored clinical tria l(s) you are currently working on or considering participation 
within. 
Protocol:
xGuidelines for COVID -19 Risk Mitigation provided in the Appendix section.
Protocol Signature [CONTACT_3490]:
xWill include a statement indicating the Princip al Investigator agrees to conduct the study in compliance 
with all local, state, and gove rnmental guidelines for COVID -19 risk mitigation.
Informed Consent:
xWill include information concerning the study -associated risks related to the COVID -19 pandemic in bold 
font and/or boxed on the first page of the Informed consent document.
COVID -[ADDRESS_1052836] for Clinical Studies:
xWill include COVID -[ADDRESS_1052837] with your respective 
[COMPANY_012] cl inical study team ( Clinical Research Associate ( CRA ),Lead CRA or Study Managers).  
Thank you for your continued engageme nt, collaboration, and dedication to your study subjects during this 
challenging time. 
Please file this letter in your s ite file study correspondence. 
CR-6435, v1.0
Page 172 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: [ADDRESS_1052838](Attachment -B):
Study Number
Site Number
Principal Investigator (PI) Name
[CONTACT_35597] -[ADDRESS_1052839] [COMPANY_012] Vison Care clinical 
studies. Please review the following requ irements and Initial each requirement.
PI [INVESTIGATOR_35471] (waiting rooms, lobby, exam rooms, etc.)
Non-contact [CONTACT_35589] p hysical distancing in waiting room
Establish longer time frame between patient appo intments to reduce persons in the site
Staff should receive job-specific training on PP E and demonstrate competen cy with selection and 
proper use of PPE and we ar at all times during interactions with subjects (e.g., putting on and 
removing without self-contamination)
PI [INVESTIGATOR_35472], site staff should regular ly monitor themselves for fever and symptoms 
of COVID-19, including temperature checks 
Any staff member (including non-study clinic staff and Investigators) showing signs of being sick 
or testing positive for COVID -[ADDRESS_1052840] and the Sponsor shall be informed
NOTE: Inform JJVC in [ADDRESS_1052841] 20 seconds or use an alcohol-based hand sanitizer 
when they arrive, before and after each patien t, before eating and after using the bathroom.
Cleaning and disinfection procedures for exam rooms and instruments or equipment between 
patients with gloves.
Cleaning and disinfection procedures for commonl y touched surfaces (doors, chairs, computers, 
phones, etc.) with gloves.
PI [INVESTIGATOR_35473] a Patient or Study Visit:
Patients should be asked prior to entering the s ite about fever and respir atory illness and whether 
they or a family member have had contact [CONTACT_35590] -[ADDRESS_1052842] patients that comp anions should remain outside of the facility and not accompany the 
patient into the facility unless they  are a parent/guardian of the patient or if they are a true 
caregiver and need to assist the patient
Request the patient to  call or text the office upon arrival so entrance to and movement through 
facility can be coordi nated by [CONTACT_35591]-6435, v1.0
Page 173 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
PI [INVESTIGATOR_35474]:
Temperature checks utilizing a non-contact [CONTACT_35592].
All patients and companions must wear cloth  or disposable mask at all times in the site
Maintain social distancing. Waiting rooms or lobbies should be as empty as possible. Advise 
seated patients to remain at le ast 6 feet from one another. 
Communal objects in (e.g. toys, reading materials, etc.) should be  removed or cleaned regularly.
I certify that I have read and agre e to implement a ll the listed COVID -[ADDRESS_1052843] of [COMPANY_012] Vision Care studies. 
Principal Investigator [INVESTIGATOR_35475]-6435, v1.0
Page 174 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
RESOURCE LINKS
US Resource Links 
xOSHA Training
https://www.osha.gov/SLTC/covid -19/controlprevention.html
Personal Protective Equipment ( PPE)Training
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/using -ppe.html
xI&R Training
ACUVUE®LensAssist: https://www.acuvue.com/lensassist    
xClinic Preparedness Guides
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/clini c-preparedness.html
AOA: https://aoa.uberflip.com/i/1240437 -aoa-guidance -for-re-opening -practices -covid·19/1?m4=
American Optom etric Association: https://www.aoa.org/optometry -practice -reactivation -preparedness -
guide
xln-Office Disinfection of Multi -Patient Use Diagnostic Contact [CONTACT_19609]://www.gpli.info/wp -content/uploads/2020/03/2020 -01-15-in-office -disinfecting -of-diagnostic -
lenses.pdf
OUS Resource Links 
xUpdates on local regulations in Hong Kong
https://www.coronavirus.gov.hk/eng/index.html
xResumption of optical services in England: Letter from Matt Neligan and Poonam Sharma
https://www.england.nhs.uk/coronavi rus/wp -content/uploads/sites/52/2020/04/C0601 -reopening -of-optical -
services -letter -17-june-2020.pdf
xNHS Optical Letter
https:/ /www.england.nhs.uk/coronavirus/wp -content/uploads/sites/52/2020/04/C0127 -optical -letter -1-april-
2020.pdf
xThe College of Opto metrists primary eye care COVID -19 guidance: Red phase
https://www.college -optometrists.org/the -college/media -hub/news -listing/coronavirus -covid -19-guidance -
for-optometrists .html
xThe College of Optometrists COVID -19: College updates
https://www.college -optometrists.org/t he-college/media -hub/news -listing/coronavirus -2019 -advice -for-
optometrists.html# CollegeGuidelines
xInfection Control Guidelines. (n .d.). Retrieved from Canadian  Association Of Optometrists: 
https://opto.ca/sites/defau lt/files/resources/docume nts/infection_control_guidelines_2016.pdf
xInfection prevention an d control for COVID -19: Interim guidance for outpatient and ambulatory care 
settings. (2020, May 23 May). Retrieved from Govern ment of Canada: https ://www.canada.ca/en/public -
health/services/ diseases/2019 -novel -coronavirus -infection/guidance -documents/interim -guidance -
outpatient -ambulatory -care-settings .html
CR-6435, v1.0
Page 175 of 177JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
xInformation for Members On Coronavirus (COVID -19). (n.d.). Retrieved from Canadian Association Of
Optometrists: 
https://opto.ca/sites/def ault/files/resources/documents/information_for_members_on_coronavirus.pdf
xCoronavirus (COVID -19) resources for health professionals, in cluding aged care providers, pathology 
providers and health care managers. (2020, September 24). Retrieved from Australian Government 
Department of Health:
https://www.health.gov.au/res ources/collections/coronavirus -covid -19-resources -for-health -professionals -
including -aged -care-providers -pathology -providers -and-health -care-managers
 
xEnvironmental Cleaning and Disinfection Principles for COVID -19. (n.d.). Retrieved from Australian 
Government Department of Health: 
https://www.health.gov.au/s ites/default/files/documents /2020/03/environmental -cleaning -and-disinfection -
principles -for-covid -19.pdf
xInfection control guidelines and advice. (n .d.). Retrieved from Optometry Australia : 
https://www.optometry.org.au/practice -professional -support/coronavirus -covid -19-what -optometrists -need -
to-know/covid -19-clinical -advice/infection -control -guideline s-and-advice/
 
CR-6435, v1.0
Page 176 of 177JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
PROTOCOL COMPLIANCE INVEST IGATOR(S) SIGNATURE [CONTACT_93962]: CR-[ADDRESS_1052844] Lenses
Version and Date: 1.0,[ADDRESS_1052845] this study according to ISO [ZIP_CODE] ,1GCP and ICH guidelines ,2the Declaration of 
Helsinki ,3[LOCATION_002] (US) Code of Federal Regulations (CFR) ,4and the pertinent individua l country 
laws/regulations and to comply with its obligations, subject to ethical and safety considerations. The 
Principal Investigator [INVESTIGATOR_19539], including Sub -
Investigators adhere to all ICH2regulations and GCP guidelines regarding clinical trials during and 
after study completion.
I will assure that no deviation from or changes to the protocol wi ll take place without prior agreement 
from the Sponsor and documented approval from the Institutional Review Board (IRB), except where 
necessary to eliminate an immediate hazard(s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub -Investigators adhere to all 
ICH2regulations and GCP guidelines regarding clinical trials during and after study compl etion.
All clinical site personnel invo lved in the conduct of this study have completed Human Subjects 
Protection Training. 
I agree to ensure that all clinical site personnel in volved in the conduct of this study are informed about 
their obligations in meeting the above commitments.
I shall not disclose the information contained in this  protocol or any results obtained from this study 
without written authorization.
I have read the suggested guidance provided by [CONTACT_19610] -19 risk mit igation, 
(COVID -19 Work Instruction in the Appendix Iof this protocol). I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks.
Principal Investigator:
[INVESTIGATOR_19540] (Printed)
Institution/Site:
Institution/Site Name
[CONTACT_16277]/Site Address
CR-6435, v1.0
Page 177 of 177JJVC CONFIDENTIAL